[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 753
1. Rodina AV, Gukasova NV, Makarov VA, Kondrasheva IG, Khomyakova AV, Posypanova GA, Popova ON, Moskaleva EY, Severin SE: Localization of Mullerian inhibiting substance receptors in various human cancer cell lines. Biochemistry (Mosc); 2008 Jul;73(7):797-805
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Localization of Mullerian inhibiting substance receptors in various human cancer cell lines.
  • Recombinant human MIS (rhMIS) produced in transfected Chinese hamster ovary cells has been purified by immunoaffinity chromatography.
  • Flow cytometry performed on MIS-sensitive cancer cell lines demonstrated specific binding of rhMIS.
  • The immunopurified rhMIS caused significant growth inhibition of ovarian and prostate adenocarcinoma and melanoma human cell lines in inhibition assays.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18707588.001).
  • [ISSN] 0006-2979
  • [Journal-full-title] Biochemistry. Biokhimii︠a︡
  • [ISO-abbreviation] Biochemistry Mosc.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Receptors, Peptide; 0 / Receptors, Transforming Growth Factor beta; 0 / Recombinant Proteins; 0 / anti-Mullerian hormone receptor; 80497-65-0 / Anti-Mullerian Hormone
  •  go-up   go-down


2. Yilmaz Z, Bese T, Demirkiran F, Ilvan S, Sanioglu C, Arvas M, Kosebay D: Skin metastasis in ovarian carcinoma. Int J Gynecol Cancer; 2006 Jan-Feb;16 Suppl 1:414-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Skin metastasis in ovarian carcinoma.
  • We report a case of 69-year-old woman who presented with pleural metastasis of a serous papillary adenocarcinoma of the ovary.
  • The skin biopsy revealed metastasis of adenocarcinoma in the dermis.
  • She died after 4 months of the diagnosis of the skin metastasis.
  • In 20 years experience in our unit, it is the first time that we recognize a cutaneous metastasis in ovarian cancer.
  • [MeSH-major] Adenocarcinoma, Papillary / secondary. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Ovarian Neoplasms / pathology. Pleural Neoplasms / secondary. Skin Neoplasms / secondary

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16515636.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


3. Judson K, McCormick C, Vang R, Yemelyanova AV, Wu LS, Bristow RE, Ronnett BM: Women with undiagnosed colorectal adenocarcinomas presenting with ovarian metastases: clinicopathologic features and comparison with women having known colorectal adenocarcinomas and ovarian involvement. Int J Gynecol Pathol; 2008 Apr;27(2):182-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Women with undiagnosed colorectal adenocarcinomas presenting with ovarian metastases: clinicopathologic features and comparison with women having known colorectal adenocarcinomas and ovarian involvement.
  • Recognition of an ovarian tumor as a metastasis from an undiagnosed primary gastrointestinal tract carcinoma can be difficult when specific symptoms referable to the primary tumor are lacking and the tumor simulates a primary ovarian neoplasm grossly and microscopically.
  • Ovarian metastases of colorectal adenocarcinomas, in particular, continue to pose diagnostic challenges both clinically and pathologically.
  • Clinicopathologic features of 20 cases of ovarian metastases from undiagnosed colorectal adenocarcinomas (U-CRAs) were compared with those of 22 cases having metastases from known colorectal adenocarcinomas (K-CRAs).
  • Women with ovarian metastases from U-CRAs were significantly younger (mean age, 48 years; median, 47 years) than those with ovarian metastases from K-CRAs (mean, 61 years; median, 63 years) (P = 0.002), presented with clinical findings related to the ovarian metastases, often had elevated CA-125 levels, and lacked specific symptoms due to the colorectal carcinomas, which were diagnosed only at the time of intraoperative evaluation of the ovarian tumors.
  • Mean/median ovarian tumor sizes (12.8/13.0 cm for U-CRAs; 14.1/15.8 cm for K-CRAs) and frequencies of bilaterality (45% for U-CRAs and 36% for K-CRAs) were not significantly different for the 2 groups; frequencies of clinically unilateral tumors of more than 10 cm were similar in both groups (30% for U-CRAs and 45% for KCRAs).
  • Other features more commonly observed in ovarian metastases from U-CRAs included mucinous differentiation, extracellular mucin production, and some degree of cytokeratin 7 expression; endometrioid-like differentiation was more common in metastases from K-CRA, but a garland pattern of necrosis and the presence of a confluent glandular, rather than infiltrative, pattern of invasion were similarly common in both groups.
  • In cases having ovarian metastases from U-CRA, the younger age of the women, uniform presentation as pelvic masses without symptoms referable to the bowel, elevated CA-125 levels, occasional presentation as a large clinically unilateral tumor, frequent mucinous differentiation, and frequent coexpression of cytokeratin 7 are features that can contribute to misclassification of these metastases as primary ovarian neoplasms.
  • [MeSH-major] Adenocarcinoma / diagnosis. Adenocarcinoma / secondary. Colorectal Neoplasms / diagnosis. Colorectal Neoplasms / pathology. Ovarian Neoplasms / diagnosis. Ovarian Neoplasms / secondary
  • [MeSH-minor] Adult. Age Factors. Aged. Aged, 80 and over. Biomarkers, Tumor / metabolism. CA-125 Antigen / metabolism. Diagnosis, Differential. Female. Humans. Keratin-7 / metabolism. Middle Aged. Mucins / metabolism. Neoplasms, Unknown Primary / diagnosis. Neoplasms, Unknown Primary / metabolism. Neoplasms, Unknown Primary / pathology. Ovary / metabolism. Ovary / pathology. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18317225.001).
  • [ISSN] 1538-7151
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CA-125 Antigen; 0 / Keratin-7; 0 / Mucins
  •  go-up   go-down


Advertisement
4. Rossing MA, Cushing-Haugen KL, Wicklund KG, Doherty JA, Weiss NS: Risk of epithelial ovarian cancer in relation to benign ovarian conditions and ovarian surgery. Cancer Causes Control; 2008 Dec;19(10):1357-64
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Risk of epithelial ovarian cancer in relation to benign ovarian conditions and ovarian surgery.
  • OBJECTIVE: Some forms of ovarian neoplasms may be preventable through the removal of precursor lesions.
  • We assessed the risk associated with a prior diagnosis of, and ovarian surgery following, ovarian cysts and endometriosis, with a focus on characterizing risk among tumor subgroups.
  • METHODS: Information was collected during in-person interviews with 812 women with ovarian cancer diagnosed in western Washington State from 2002 to 2005 and 1,313 population-based controls.
  • RESULTS: The risk of a borderline mucinous ovarian tumor associated with a history of an ovarian cyst was increased (OR=1.7, 95% CI: 1.0-2.8), but did not vary notably according to receipt of subsequent ovarian surgery.
  • While risk of invasive epithelial ovarian cancer was slightly increased among women with a cyst who had no subsequent ovarian surgery, it was reduced when a cyst diagnosis was followed by surgery (OR = 0.6, 95% CI: 0.4-0.9).
  • Women with a history of endometriosis had a threefold increased risk of endometrioid and clear cell invasive tumors, with a lesser risk increase among women who underwent subsequent ovarian surgery.
  • CONCLUSIONS: Our results suggest differences in the relation of ovarian cysts and endometriosis with risk of specific subtypes of ovarian cancer as well as the possibility that ovarian surgery in women with these conditions may lower the risk of invasive disease.

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Ovarian epithelial cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Epidemiol. 2000 Jan;10(1):14-23 [10658685.001]
  • [Cites] Cancer Causes Control. 2008 May;19(4):413-20 [18080774.001]
  • [Cites] Lancet. 2000 Mar 25;355(9209):1060-3 [10744092.001]
  • [Cites] Eur J Cancer Prev. 2001 Apr;10(2):197-9 [11330466.001]
  • [Cites] Gynecol Oncol. 2001 Oct;83(1):100-8 [11585420.001]
  • [Cites] Am J Epidemiol. 2002 Feb 1;155(3):217-24 [11821246.001]
  • [Cites] Am J Obstet Gynecol. 2003 Jul;189(1):280-94 [12861175.001]
  • [Cites] Acta Obstet Gynecol Scand. 2004 Apr;83(4):395-400 [15005789.001]
  • [Cites] Am J Pathol. 2004 May;164(5):1511-8 [15111296.001]
  • [Cites] Int J Gynecol Pathol. 2004 Jul;23(3):200-5 [15213595.001]
  • [Cites] Epidemiology. 1996 May;7(3):319-22 [8728451.001]
  • [Cites] Int J Epidemiol. 1997 Aug;26(4):710-5 [9279601.001]
  • [Cites] Eur J Cancer. 1997 Sep;33(10):1634-7 [9389926.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Feb;14(2):299-305 [15734950.001]
  • [Cites] Mod Pathol. 2005 Feb;18 Suppl 2:S19-32 [15761464.001]
  • [Cites] Gynecol Oncol. 2005 May;97(2):318-22 [15863124.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Dec;14(12):2929-35 [16365012.001]
  • [Cites] Hum Reprod. 2006 May;21(5):1237-42 [16431901.001]
  • [Cites] Cancer Causes Control. 2006 Jun;17(5):623-32 [16633908.001]
  • [Cites] J Pathol. 2007 Jan;211(1):26-35 [17117391.001]
  • [Cites] Curr Opin Obstet Gynecol. 2007 Feb;19(1):3-9 [17218844.001]
  • [Cites] Int J Gynecol Cancer. 2007 Jan-Feb;17(1):37-43 [17291229.001]
  • [Cites] Clin Med Res. 2007 Mar;5(1):35-44 [17456833.001]
  • [Cites] Gynecol Oncol. 2007 Nov;107(2):223-30 [17662378.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 Dec;16(12):2548-56 [18086757.001]
  • [Cites] Lancet. 2000 Mar 25;355(9209):1028-9 [10744081.001]
  • (PMID = 18704718.001).
  • [ISSN] 1573-7225
  • [Journal-full-title] Cancer causes & control : CCC
  • [ISO-abbreviation] Cancer Causes Control
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA087538-01A2; United States / NCI NIH HHS / CA / R01 CA087538-05; United States / NCI NIH HHS / CA / R01 CA087538; United States / NCI NIH HHS / CA / R01 CA87538; United States / NCI NIH HHS / CA / R01 CA087538-02; United States / NCI NIH HHS / CA / CA087538-05; United States / NCI NIH HHS / CA / R01 CA087538-03; United States / NCI NIH HHS / CA / R01 CA087538-04; United States / NCI NIH HHS / CA / CA087538-01A2
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] Netherlands
  • [Other-IDs] NLM/ NIHMS146032; NLM/ PMC2751585
  •  go-up   go-down


5. Mhawech-Fauceglia P, Odunsi K, Dim D, Nowak N, Lele S, Cheney RT, Pejovic T: Array-comparative genomic hybridization analysis of primary endometrial and ovarian high-grade neuroendocrine carcinoma associated with adenocarcinoma: mystery resolved? Int J Gynecol Pathol; 2008 Oct;27(4):539-46
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Array-comparative genomic hybridization analysis of primary endometrial and ovarian high-grade neuroendocrine carcinoma associated with adenocarcinoma: mystery resolved?
  • High-grade neuroendocrine carcinomas (NECs) of the uterine corpus and ovary are very rare tumors, and whenever diagnosed, they are usually associated with epithelial carcinoma.
  • To shed some light, we studied the genetic abnormalities of each of the 2 components, NEC and adenocarcinoma, in 4 cases arising in the ovary and the uterine corpus using array-comparative genomic hybridization.
  • However, the NEC component showed numerous additional genetic abnormalities in comparison with the adenocarcinomas including gain on 6p25.3-p21.2 and 19q12 and losses on 6q24.2-q27, 19q13.11-13.2, and 19q13.31-13.41, where numerous genes involved in the pathogenesis of epithelial ovarian carcinoma have been previously identified.
  • However, the NEC components exhibited more genetic abnormalities in comparison with the adenocarcinoma, suggesting that when the NEC clones become more dedifferentiated, they acquire additional genetic abnormalities.
  • [MeSH-major] Adenocarcinoma / genetics. Carcinoma, Neuroendocrine / genetics. Endometrial Neoplasms / genetics. Ovarian Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18753966.001).
  • [ISSN] 1538-7151
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Neoplasm
  •  go-up   go-down


6. Ciocca V, Bombonati A, Palazzo JP, Schulz S, Waldman SA: Guanylyl cyclase C is a specific marker for differentiating primary and metastatic ovarian mucinous neoplasms. Histopathology; 2009 Aug;55(2):182-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Guanylyl cyclase C is a specific marker for differentiating primary and metastatic ovarian mucinous neoplasms.
  • AIMS: The aim was to assess the value of GCC in distinguishing primary ovarian mucinous neoplasms from metastatic mucinous adenocarcinomas with ovarian involvement.
  • METHODS AND RESULTS: Fifty ovarian tumours: 27 primary ovarian mucinous neoplasms (seven cystadenomas, 10 borderline tumours and 10 cystadenocarcinomas) and 23 metastatic mucinous adenocarcinomas with ovarian involvement [13 colorectal adenocarcinomas, four gastric adenocarcinomas, six appendiceal mucinous tumours (four adenocarcinomas, one with neuroendocrine features, and two appendiceal mucinous cystadenomas)] were studied.
  • For primary ovarian mucinous neoplasms, 25 of 27 were negative for GCC.
  • Twelve of 13 cases of colorectal adenocarcinoma (except for one neuroendocrine adenocarcinoma) were positive for GCC.
  • Three of four appendiceal mucinous adenocarcinomas were positive for GCC in both the primary and metastatic tumours (except for one neuroendocrine adenocarcinoma).
  • Of four cases of gastric adenocarcinoma with ovarian involvement, only one (primary tumour) exhibited focal GCC staining.
  • CONCLUSIONS: GCC is a useful marker for differentiating between primary and secondary ovarian mucinous neoplasms.

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gastroenterology. 2000 Jul;119(1):89-96 [10889158.001]
  • [Cites] Mod Pathol. 2006 Nov;19(11):1421-8 [16980943.001]
  • [Cites] Cancer Res. 2000 Sep 15;60(18):5151-7 [11016642.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Jul 3;98(14):7846-51 [11438734.001]
  • [Cites] Am J Surg Pathol. 2003 Mar;27(3):281-92 [12604884.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Mar 4;100(5):2695-9 [12594332.001]
  • [Cites] Am J Surg Pathol. 2003 Jul;27(7):985-93 [12826891.001]
  • [Cites] Virchows Arch. 2003 Dec;443(6):782-6 [14576939.001]
  • [Cites] Am J Physiol. 1983 Oct;245(4):G492-8 [6312810.001]
  • [Cites] Cell. 1990 Nov 30;63(5):941-8 [1701694.001]
  • [Cites] J Biol Chem. 1991 Sep 25;266(27):17912-8 [1680854.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Feb 1;89(3):947-51 [1346555.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Nov 15;90(22):10464-8 [7902563.001]
  • [Cites] J Anat. 1994 Apr;184 ( Pt 2):407-17 [8014132.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Dec 10;93(25):14827-32 [8962140.001]
  • [Cites] Am J Surg Pathol. 1997 Oct;21(10):1144-55 [9331286.001]
  • [Cites] Am J Surg Pathol. 1999 Jun;23(6):617-35 [10366144.001]
  • [Cites] Mod Pathol. 2005 Jan;18(1):19-25 [15389251.001]
  • [Cites] Hum Pathol. 2005 Feb;36(2):170-9 [15754294.001]
  • [Cites] Int J Gynecol Pathol. 2006 Jan;25(1):83-9 [16306790.001]
  • [Cites] Mod Pathol. 2006 Jan;19(1):97-105 [16294196.001]
  • [Cites] Am J Surg Pathol. 2006 Sep;30(9):1130-9 [16931958.001]
  • [Cites] Mod Pathol. 2000 Sep;13(9):962-72 [11007036.001]
  • (PMID = 19694825.001).
  • [ISSN] 1365-2559
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA75123; United States / NCI NIH HHS / CA / R01 CA075123-04; United States / NCI NIH HHS / CA / R01 CA095026-04; United States / NCI NIH HHS / CA / R01 CA095026; United States / NCI NIH HHS / CA / CA95026; United States / NCI NIH HHS / CA / R01 CA075123
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Receptors, Peptide; EC 4.6.1.2 / Guanylate Cyclase; EC 4.6.1.2 / Receptors, Guanylate Cyclase-Coupled; EC 4.6.1.2 / enterotoxin receptor
  • [Other-IDs] NLM/ NIHMS309367; NLM/ PMC3140017
  •  go-up   go-down


7. Dahlstedt E, Collins HA, Balaz M, Kuimova MK, Khurana M, Wilson BC, Phillips D, Anderson HL: One- and two-photon activated phototoxicity of conjugated porphyrin dimers with high two-photon absorption cross sections. Org Biomol Chem; 2009 Mar 7;7(5):897-904
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • These dimers demonstrate high one-photon PDT efficacy against a human ovarian adenocarcinoma cell line (SK-OV-3) and exhibit no significant dark-toxicity at concentrations of up to 20 microM.
  • [MeSH-minor] Cell Line, Tumor. Dimerization. Female. Humans. Infrared Rays. Ovarian Neoplasms / therapy. Photons. Photosensitizing Agents / pharmacology. Solubility

  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19225672.001).
  • [ISSN] 1477-0539
  • [Journal-full-title] Organic & biomolecular chemistry
  • [ISO-abbreviation] Org. Biomol. Chem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Photosensitizing Agents; 0 / Porphyrins; 129497-78-5 / verteporfin
  •  go-up   go-down


8. Karlberg S, Lipsanen-Nyman M, Lassus H, Kallijärvi J, Lehesjoki AE, Butzow R: Gynecological tumors in Mulibrey nanism and role for RING finger protein TRIM37 in the pathogenesis of ovarian fibrothecomas. Mod Pathol; 2009 Apr;22(4):570-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gynecological tumors in Mulibrey nanism and role for RING finger protein TRIM37 in the pathogenesis of ovarian fibrothecomas.
  • More than half of female patients with Mulibrey nanism develop benign mesenchymal tumors of ovarian sex cord-stromal origin.
  • In addition to tumors of the fibrothecoma group, 18% (4/22) of the patients were observed with epithelial neoplasias, including 2 ovarian adenofibromas, 1 ovarian poorly differentiated adenocarcinoma and 1 endometrial adenocarcinoma.
  • TRIM37del2 was also found in normal ovary but in a proportion of sporadic fibrothecomas, the TRIM37del2:TRIM37 ratio was increased.
  • In normal ovary, TRIM37 was localized in the cytoplasm of stromal cells, especially theca cells surrounding developing follicles.
  • In conclusion, inherited biallelic inactivation of TRIM37 (Mulibrey nanism) predisposes to both mesenchymal and epithelial ovarian tumors and dysregulation of TRIM37 may also be involved in the pathogenesis of sporadic fibrothecomas.
  • [MeSH-major] Mulibrey Nanism / complications. Nuclear Proteins / genetics. Nuclear Proteins / metabolism. Ovarian Neoplasms / genetics. Thecoma / genetics

  • Genetic Alliance. consumer health - Mulibrey Nanism.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • SciCrunch. Clinical Genomic Database: Data: Gene Annotation .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19329943.001).
  • [ISSN] 1530-0285
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Nuclear Proteins; 0 / Protein Isoforms; 0 / TRIM37 protein, human
  •  go-up   go-down


9. Busquets M, Gonzalez-Bosquet E, Muchart J, Rovira C, Laïlla JM: Granulosa cell tumor and endometrial cancer: a case report and review of the literature. Eur J Gynaecol Oncol; 2010;31(5):575-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Granulosa cell tumor and endometrial cancer: a case report and review of the literature.
  • Granulosa cell tumors (GCTs) of the ovary are an uncommon type of ovarian cancer, representing only 2-5%.
  • As a consequence, this neoplasia can be diagnosed either by common ovarian cancer symptoms or endometrial pathologies due to an estrogenic effect.
  • Once endometrial cancer was diagnosed and subsequently staged, an ovarian mass was detected.
  • We report an atypical case of ovarian cancer with the aim of reviewing the clinical features of GCT, as well as its prognosis, treatment and follow-up recommendations, according to the available literature.
  • [MeSH-major] Adenocarcinoma / pathology. Endometrial Neoplasms / pathology. Granulosa Cell Tumor / pathology. Neoplasms, Multiple Primary. Ovarian Neoplasms / pathology

  • Genetic Alliance. consumer health - Endometrial cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21061806.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Italy
  •  go-up   go-down


10. Köbel M: [Ovarian carcinoma. Do the subtypes reflect different diseases?]. Pathologe; 2008 Nov;29 Suppl 2:160-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Ovarian carcinoma. Do the subtypes reflect different diseases?].
  • Lack of therapeutic options and poor reproducibility of histopathological subtypes have been the reasons that ovarian carcinomas are currently treated as monolithic entity.
  • [MeSH-major] Ovarian Neoplasms / classification. Ovarian Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma, Clear Cell / classification. Adenocarcinoma, Clear Cell / genetics. Adenocarcinoma, Clear Cell / pathology. Adenocarcinoma, Mucinous / classification. Adenocarcinoma, Mucinous / genetics. Adenocarcinoma, Mucinous / pathology. Carcinoma, Endometrioid / classification. Carcinoma, Endometrioid / genetics. Carcinoma, Endometrioid / pathology. Cystadenocarcinoma, Serous / classification. Cystadenocarcinoma, Serous / genetics. Cystadenocarcinoma, Serous / pathology. DNA Mutational Analysis. Diagnosis, Differential. Female. Genetic Markers / genetics. Humans. Observer Variation. Ovary / pathology. Practice Guidelines as Topic. Prognosis. Tumor Suppressor Protein p53 / genetics

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gynecol Oncol. 1998 Jul;70(1):2-12 [9698465.001]
  • [Cites] Int J Gynecol Pathol. 2002 Oct;21(4):407-11 [12352190.001]
  • [Cites] Clin Cancer Res. 2008 Jan 1;14 (1):89-96 [18172257.001]
  • [Cites] Gynecol Oncol. 2001 Feb;80(2):189-93 [11161858.001]
  • [Cites] Onkologie. 2002 Jun;25(3):240-7 [12119458.001]
  • [Cites] Br J Cancer. 2006 May 22;94(10):1369-74 [16641903.001]
  • [Cites] APMIS. 1991 Apr;99(4):353-8 [2036219.001]
  • [Cites] Gynecol Oncol. 2004 Oct;95(1):89-94 [15385115.001]
  • [Cites] BMC Cancer. 2008 Jan 22;8:17 [18208621.001]
  • [Cites] Am J Pathol. 2004 May;164(5):1511-8 [15111296.001]
  • [Cites] Hum Pathol. 2008 Aug;39(8):1239-51 [18602670.001]
  • [Cites] Cancer Res. 2002 Aug 15;62(16):4722-9 [12183431.001]
  • [Cites] Lancet. 2003 Sep 13;362(9387):869-75 [13678974.001]
  • [Cites] Gynecol Oncol. 2008 Apr;109(1):129-39 [18234305.001]
  • [Cites] Am J Surg Pathol. 2007 Aug;31(8):1168-74 [17667538.001]
  • [Cites] Breast Cancer Res Treat. 2008 Dec;112(3):453-9 [18193353.001]
  • [Cites] Am J Surg Pathol. 2009 Jan;33(1):14-21 [18830127.001]
  • [Cites] J Clin Oncol. 2003 Jan 15;21(2):283-90 [12525520.001]
  • [Cites] Am J Surg Pathol. 2005 Feb;29(2):218-24 [15644779.001]
  • [Cites] Am J Pathol. 1977 Jun;87(3):686-720 [194486.001]
  • [Cites] Int J Gynecol Pathol. 2000 Apr;19(2):158-63 [10782413.001]
  • [Cites] Mod Pathol. 2006 Apr;19(4):581-7 [16554733.001]
  • [Cites] Am J Surg Pathol. 2004 Apr;28(4):453-63 [15087664.001]
  • [Cites] Neoplasia. 2008 Sep;10(9):1021-7 [18714364.001]
  • [Cites] PLoS One. 2007 Nov 07;2(11):e1138 [17987122.001]
  • [Cites] Histopathology. 2006 Jan;48(2):149-56 [16405663.001]
  • [Cites] Nature. 2005 Apr 14;434(7035):917-21 [15829967.001]
  • [Cites] Arch Pathol Lab Med. 1991 Apr;115(4):377-81 [1672813.001]
  • (PMID = 18709371.001).
  • [ISSN] 1432-1963
  • [Journal-full-title] Der Pathologe
  • [ISO-abbreviation] Pathologe
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Genetic Markers; 0 / TP53 protein, human; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


16. Husein-ElAhmed H, Aneiros-Fernandez J, Arias-Santiago S, Naranjo-Sintes R: Sister Mary Joseph's nodule as a metastasis of ovarian adenocarcinoma. Int J Dermatol; 2010 Sep;49(9):1045-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sister Mary Joseph's nodule as a metastasis of ovarian adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / secondary. Ovarian Neoplasms / pathology. Sister Mary Joseph's Nodule / secondary. Skin Neoplasms / secondary

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. CAPECITABINE .
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20883267.001).
  • [ISSN] 1365-4632
  • [Journal-full-title] International journal of dermatology
  • [ISO-abbreviation] Int. J. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Organoplatinum Compounds; 0 / Receptors, Estrogen; 0 / Receptors, Progesterone; 0 / Vimentin; 0 / WT1 Proteins; 04ZR38536J / oxaliplatin; 0W860991D6 / Deoxycytidine; 6804DJ8Z9U / Capecitabine; BG3F62OND5 / Carboplatin; EC 3.4.24.11 / Neprilysin; P88XT4IS4D / Paclitaxel; U3P01618RT / Fluorouracil
  •  go-up   go-down


17. Medeiros F, Bell DA: Pseudoneoplastic lesions of the female genital tract. Arch Pathol Lab Med; 2010 Mar;134(3):393-403
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Several of the more common pseudoneoplastic lesions are discussed in this article, including microglandular hyperplasia of the cervix mimicking well-differentiated endometrial adenocarcinoma, reactive epithelial changes in the fallopian tubes mimicking adenocarcinoma or carcinoma in situ, and pregnancy changes in the ovary including pregnancy luteoma and large solitary luteinized follicular cyst of pregnancy and puerperium that may mimic ovarian neoplasms.
  • Awareness of the features of such lesions will aid in their correct diagnosis and prevent overtreatment of benign processes.
  • [MeSH-major] Genital Diseases, Female / diagnosis. Granuloma, Plasma Cell / diagnosis
  • [MeSH-minor] Adult. Diagnosis, Differential. Female. Genital Neoplasms, Female / classification. Genital Neoplasms, Female / diagnosis. Humans. Pregnancy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20196667.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 76
  •  go-up   go-down


18. Babu MR, Haji AG, Chitrathara K, Vijaykumar DK, Samanta J, Hiran KR: Primary transitional cell carcinoma of the fallopian tube in a premenopausal woman: A case report and review of literature. Indian J Med Paediatr Oncol; 2009 Jan;30(1):35-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In view of the elevated CA-125 and imaging findings suggestive of ovarian mass, she underwent staging laparotomy.
  • Review of available literature suggested that the primary transitional cell carcinoma is probably less aggressive compared to classical adenocarcinoma of the fallopian tube, and it has to be distinguished from the recently recognized entity, parafallopian tube transitional cell carcinoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gynecol Oncol. 2001 Jan;80(1):16-20 [11136563.001]
  • [Cites] Gynecol Oncol. 1987 Mar;26(3):305-13 [3557196.001]
  • [Cites] Gynecol Oncol. 1999 Mar;72(3):367-79 [10053109.001]
  • [Cites] Gynecol Oncol. 1998 Dec;71(3):469-75 [9887253.001]
  • [Cites] Cytojournal. 2005;2:20 [16336674.001]
  • [Cites] Oncologist. 2006 Sep;11(8):902-12 [16951394.001]
  • [Cites] Surg Clin North Am. 1978 Feb;58(1):121-9 [644422.001]
  • [Cites] Gynecol Oncol. 2002 Sep;86(3):379-83 [12217766.001]
  • [Cites] Cancer. 1993 Oct 15;72(8):2447-56 [8402462.001]
  • (PMID = 20668606.001).
  • [ISSN] 0975-2129
  • [Journal-full-title] Indian journal of medical and paediatric oncology : official journal of Indian Society of Medical & Paediatric Oncology
  • [ISO-abbreviation] Indian J Med Paediatr Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC2902214
  • [Keywords] NOTNLM ; Carcinoma ovary / fallopian tube / transitional cell carcinoma
  •  go-up   go-down


19. Hewitt MJ, Hall GD, Wilkinson N, Perren TJ, Lane G, Spencer JA: Image-guided biopsy in women with breast cancer presenting with peritoneal carcinomatosis. Int J Gynecol Cancer; 2006 Jan-Feb;16 Suppl 1:108-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Image-guided biopsy in women with breast cancer presenting with peritoneal carcinomatosis.
  • When women with a history of breast cancer present with peritoneal carcinomatosis, the differential diagnosis lies between recurrent breast cancer or a new primary tumor.
  • This scenario is of particular relevance to women with a BRCA gene mutation, who have a genetic predisposition to develop second primary tumors of the ovary, fallopian tube, and peritoneum.
  • We describe the use of image-guided core biopsy as an alternative to laparoscopy or exploratory laparotomy in providing minimally invasive diagnosis in this increasingly common clinical dilemma.
  • [MeSH-major] Adenocarcinoma / pathology. Breast Neoplasms / pathology. Mixed Tumor, Mullerian / pathology. Peritoneal Neoplasms / pathology. Peritoneum / pathology

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16515576.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


20. Pozdnyakova O, Hoang MM, Dresser KA, Mahalingam M: Prognostic value of E-cadherin, beta-catenin, CD44v6, and HER2/neu in metastatic cutaneous adenocarcinoma. Arch Pathol Lab Med; 2009 Aug;133(8):1285-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic value of E-cadherin, beta-catenin, CD44v6, and HER2/neu in metastatic cutaneous adenocarcinoma.
  • CONTEXT: Our recent experience with a patient developing cutaneous metastases within 3 months of diagnosis of esophageal adenocarcinoma suggests that altered expression of the cellular adhesion molecules, E-cadherin and CD44v6, may have had a role to play in the rapid onset of metastases.
  • DESIGN: E-cadherin, beta-catenin, CD44v6, and HER2/neu immunohistochemical stains were performed on archival materials of metastatic adenocarcinoma to the skin from 27 patients and the available corresponding primary tumors in 10 patients.
  • The primary sites included breast (n = 10; 37%), gastrointestinal tract (n = 10; 37%), ovary (n = 1; 4%), thyroid (n = 2; 7%), lung (n = 1; 4%), and unknown primary (n = 3; 11%).
  • [MeSH-major] Adenocarcinoma / metabolism. Biomarkers, Tumor / metabolism. Esophageal Neoplasms / metabolism. Neoplasm Proteins / metabolism. Skin Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19653727.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD44; 0 / Biomarkers, Tumor; 0 / CD44v6 antigen; 0 / Cadherins; 0 / Neoplasm Proteins; 0 / beta Catenin; EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


21. Kim KY, Kim SU, Leung PC, Jeung EB, Choi KC: Influence of the prodrugs 5-fluorocytosine and CPT-11 on ovarian cancer cells using genetically engineered stem cells: tumor-tropic potential and inhibition of ovarian cancer cell growth. Cancer Sci; 2010 Apr;101(4):955-62
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Influence of the prodrugs 5-fluorocytosine and CPT-11 on ovarian cancer cells using genetically engineered stem cells: tumor-tropic potential and inhibition of ovarian cancer cell growth.
  • In the present study, we evaluated whether these GESTECs were capable of migrating to human ovarian cancer cells and examined the potential therapeutic efficacy of the gene-directed enzyme prodrug therapy against ovarian cancer cells in vitro.
  • A modified transwell migration assay was performed to determine the migratory capacity of GESTECs to ovarian cancer cells.
  • GESTECs (HB1.F3.CD or HB1.F3.CE cells) engineered to express a suicide gene (CD or CE) selectively migrated toward ovarian cancer cells.
  • Treatment of human epithelial ovarian cancer cell line (SKOV-3, an ovarian adenocarcinoma derived from the ascites of an ovarian cancer patient) with the prodrugs 5-fluorocytosine (5-FC) or camptothecin-11 (CPT-11) in the presence of HB1.F3.CD or HB1.F3.CE cells resulted in the inhibition of ovarian cancer cell growth.
  • Based on the data presented herein, we suggest that GESTECs expressing CD/CE may have a potent advantage to selectively treat ovarian cancers.
  • [MeSH-major] Antimetabolites / pharmacology. Antineoplastic Agents, Phytogenic / pharmacology. Camptothecin / analogs & derivatives. Flucytosine / pharmacology. Genetic Therapy / methods. Ovarian Neoplasms / therapy. Prodrugs / pharmacology. Stem Cells

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Genes and Gene Therapy.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • MedlinePlus Health Information. consumer health - Stem Cells.
  • Hazardous Substances Data Bank. FLUCYTOSINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20704576.001).
  • [ISSN] 1349-7006
  • [Journal-full-title] Cancer science
  • [ISO-abbreviation] Cancer Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antimetabolites; 0 / Antineoplastic Agents, Phytogenic; 0 / Prodrugs; 7673326042 / irinotecan; D83282DT06 / Flucytosine; EC 3.5.4.1 / Cytosine Deaminase; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


22. Chu AY, Litzky LA, Pasha TL, Acs G, Zhang PJ: Utility of D2-40, a novel mesothelial marker, in the diagnosis of malignant mesothelioma. Mod Pathol; 2005 Jan;18(1):105-10
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Utility of D2-40, a novel mesothelial marker, in the diagnosis of malignant mesothelioma.
  • Although immunohistochemistry has proven to be valuable in the differentiation of epithelioid mesothelioma from pulmonary or metastatic adenocarcinoma, no single antibody has demonstrated absolute sensitivity or specificity in making this distinction.
  • Using immunohistochemical analysis with D2-40, a recently available monoclonal antibody that has been used as a lymphatic endothelial marker, we examined 53 cases of mesothelioma, 28 cases of reactive pleura, 30 cases of pulmonary adenocarcinoma, 35 cases of renal cell carcinoma, 26 cases of ovarian serous carcinoma, 16 cases of invasive breast carcinoma, 11 cases of prostatic adenocarcinoma, and seven cases of urothelial carcinoma.
  • In addition, immunohistochemistry using calretinin, cytokeratin 5/6, and WT1 was performed on all cases of mesothelioma, pulmonary adenocarcinoma, ovarian serous carcinoma, and renal cell carcinoma.
  • Predominantly, membranous D2-40 immunoreactivity was present in 51 of 53 (96%) mesotheliomas, 27 of 28 (96%) cases of reactive pleura, and 17 of 26 (65%) ovarian serous carcinomas; membranous staining was not seen in any other tumors examined.
  • We conclude that D2-40 immunoreactivity is sensitive for cells of mesothelial origin, and may be useful in the differential diagnosis of epithelioid malignant mesothelioma vs adenocarcinoma.
  • [MeSH-major] Antibodies, Monoclonal. Biomarkers, Tumor. Mesothelioma / diagnosis

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • COS Scholar Universe. author profiles.
  • antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15389250.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / monoclonal antibody D2-40; 0 / oncofetal antigens
  •  go-up   go-down


23. Solár P, Horváth V, Kleban J, Koval' J, Solárová Z, Kozubík A, Fedorocko P: Hsp90 inhibitor geldanamycin increases the sensitivity of resistant ovarian adenocarcinoma cell line A2780cis to cisplatin. Neoplasma; 2007;54(2):127-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hsp90 inhibitor geldanamycin increases the sensitivity of resistant ovarian adenocarcinoma cell line A2780cis to cisplatin.
  • Ovarian carcinoma is the leading cause of death among gynecological neoplasms in the world.
  • The chemoresistance is a major obstacle in the effective treatment of ovarian and other cancers.
  • We evaluated the effects of Hsp90 inhibitor geldanamycin (GEL) alone and in combination with cisplatin in cisplatin resistant ovarian adenocarcinoma cell line.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Benzoquinones / pharmacology. Cisplatin / pharmacology. Drug Resistance, Neoplasm. Enzyme Inhibitors / pharmacology. HSP90 Heat-Shock Proteins / antagonists & inhibitors. Lactams, Macrocyclic / pharmacology. Ovarian Neoplasms / drug therapy
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / pathology. Blotting, Western. Cell Cycle / drug effects. Cell Proliferation / drug effects. Female. Humans. Tumor Cells, Cultured / drug effects

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17319785.001).
  • [ISSN] 0028-2685
  • [Journal-full-title] Neoplasma
  • [ISO-abbreviation] Neoplasma
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Slovakia
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzoquinones; 0 / Enzyme Inhibitors; 0 / HSP90 Heat-Shock Proteins; 0 / Lactams, Macrocyclic; Q20Q21Q62J / Cisplatin; Z3K3VJ16KU / geldanamycin
  •  go-up   go-down


24. Batra S, Singh M, Wynn JS: An unusual case of primary fallopian tube carcinoma in pregnancy. Int J Gynecol Cancer; 2006 Jan-Feb;16 Suppl 1:365-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A staging laparotomy in the postnatal period showed no spread of tumor, and in view of her age and desire for further pregnancies, her uterus and other ovary and tube were conserved.
  • [MeSH-major] Adenocarcinoma, Papillary / surgery. Fallopian Tube Neoplasms / surgery. Pregnancy Complications, Neoplastic

  • Genetic Alliance. consumer health - Pregnancy.
  • MedlinePlus Health Information. consumer health - Tumors and Pregnancy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16515625.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


25. Roth LM, Miller AW 3rd, Talerman A: Typical thyroid-type carcinoma arising in struma ovarii: a report of 4 cases and review of the literature. Int J Gynecol Pathol; 2008 Oct;27(4):496-506
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Upon review of the literature, papillary carcinoma and follicular carcinoma are the most frequent types of malignancy to occur in ovarian struma; other forms of thyroid carcinoma occur only rarely.
  • In reference to follicular carcinoma, invasion into the surrounding ovarian tissue, vascular invasion, or metastasis is evidence of malignancy.
  • Histological malignancy in a struma does not necessarily equate with biological malignancy, and the majority of thyroid-type carcinomas do not spread beyond the ovary.
  • Occasionally, metastases of ovarian struma have an innocuous histological appearance, and such cases are referred to as highly differentiated follicular carcinoma of ovarian origin (HDFCO).
  • Because its histological appearance resembles that of nonneoplastic thyroid, HDFCO characteristically cannot be diagnosed until the neoplasm spreads beyond the ovary.
  • In this article, we apply the term typical thyroid carcinoma to those forms of thyroid malignancy arising in ovarian struma that closely resemble the types described in the cervical thyroid gland to distinguish them from HDFCO.
  • Cases of thyroid-type carcinoma arising in the ovary sometimes lack evidence of preexisting struma.
  • Primary thyroid-type carcinoma must be distinguished from rare instances of ovarian metastases that originate in the cervical thyroid gland and the less differentiated forms from other ovarian neoplasms such as clear cell adenocarcinoma and tumors with an oxyphilic appearance.
  • In the differential diagnosis with other ovarian neoplasms, cases of thyroid-type carcinoma associated with strumal carcinoid should not be diagnosed as malignant strumal carcinoid because the latter diagnosis might lead to suboptimal therapy.
  • [MeSH-major] Adenocarcinoma, Follicular / pathology. Carcinoid Tumor / pathology. Carcinoma, Papillary / pathology. Ovarian Neoplasms / pathology. Struma Ovarii / pathology. Thyroid Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18753973.001).
  • [ISSN] 1538-7151
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


26. Preston DL, Ron E, Tokuoka S, Funamoto S, Nishi N, Soda M, Mabuchi K, Kodama K: Solid cancer incidence in atomic bomb survivors: 1958-1998. Radiat Res; 2007 Jul;168(1):1-64
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Solid cancer incidence in atomic bomb survivors: 1958-1998.
  • The analyses were based on 17,448 first primary cancers (including non-melanoma skin cancer) diagnosed from 1958 through 1998 among 105,427 cohort members with individual dose estimates who were alive and not known to have had cancer prior to 1958.
  • Radiation-associated relative risks and excess rates were considered for all solid cancers as a group, for 19 specific cancer sites or groups of sites, and for five histology groups.
  • It was estimated that, at age 70 after exposure at age 30, solid cancer rates increase by about 35% per Gy (90% CI 28%; 43%) for men and 58% per Gy (43%; 69%) for women.
  • Despite the decline in the ERR with attained age, excess absolute rates appeared to increase throughout the study period, providing further evidence that radiation-associated increases in cancer rates persist throughout life regardless of age at exposure.
  • Significant radiation-associated increases in risk were seen for most sites, including oral cavity, esophagus, stomach, colon, liver, lung, non-melanoma skin, breast, ovary, bladder, nervous system and thyroid.
  • However, there was emerging evidence from the present data that exposure as a child may increase risks of cancer of the body of the uterus.
  • Elevated risks were seen for all of the five broadly classified histological groups considered, including squamous cell carcinoma, adenocarcinoma, other epithelial cancers, sarcomas and other non-epithelial cancers.
  • Although the data were limited, there was a significant radiation-associated increase in the risk of cancer occurring in adolescence and young adulthood.
  • In view of the persisting increase in solid cancer risks, the LSS should continue to provide important new information on radiation exposure and solid cancer risks for at least another 15 to 20 years.

  • MedlinePlus Health Information. consumer health - Cancer in Children.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17722996.001).
  • [ISSN] 0033-7587
  • [Journal-full-title] Radiation research
  • [ISO-abbreviation] Radiat. Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CP / N01-CP-31021; United States / Intramural NIH HHS / /
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


27. Blich M, Malkin L, Kapeliovich M: Malignant pericardial tamponade secondary to papillary serous adenocarcinoma of the ovary. Isr Med Assoc J; 2007 Apr;9(4):337-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant pericardial tamponade secondary to papillary serous adenocarcinoma of the ovary.
  • [MeSH-major] Cardiac Tamponade / etiology. Cystadenocarcinoma, Papillary / secondary. Mediastinal Neoplasms / secondary. Ovarian Neoplasms / pathology. Pericardium
  • [MeSH-minor] Aged. Antineoplastic Agents / therapeutic use. Biopsy. Diagnosis, Differential. Fatal Outcome. Female. Humans. Ovariectomy. Pericardiocentesis

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • MedlinePlus Health Information. consumer health - Pericardial Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17491236.001).
  • [ISSN] 1565-1088
  • [Journal-full-title] The Israel Medical Association journal : IMAJ
  • [ISO-abbreviation] Isr. Med. Assoc. J.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Israel
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


28. Hecht JL, Dolinski BM, Gardner HA, Violette SM, Weinreb PH: Overexpression of the alphavbeta6 integrin in endometrial cancer. Appl Immunohistochem Mol Morphol; 2008 Dec;16(6):543-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Overexpression of the alphavbeta6 integrin in endometrial cancer.
  • The alpha(v)beta(6) integrin (alphavbeta6) has been shown to be up-regulated in adenocarcinoma of the breast, colon, stomach, and ovary, generally reflecting a more aggressive phenotype.
  • Expression in endometrial cancer has not been reported.

  • Genetic Alliance. consumer health - Endometrial cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18698261.001).
  • [ISSN] 1533-4058
  • [Journal-full-title] Applied immunohistochemistry & molecular morphology : AIMM
  • [ISO-abbreviation] Appl. Immunohistochem. Mol. Morphol.
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Integrin alphaV; 0 / Integrin beta Chains; 0 / integrin beta6
  •  go-up   go-down


29. Kusuda T, Shigemasa K, Arihiro K, Fujii T, Nagai N, Ohama K: Relative expression levels of Th1 and Th2 cytokine mRNA are independent prognostic factors in patients with ovarian cancer. Oncol Rep; 2005 Jun;13(6):1153-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Relative expression levels of Th1 and Th2 cytokine mRNA are independent prognostic factors in patients with ovarian cancer.
  • The aim of the present study was to examine mRNA expression levels of Th1 (TNF-alpha , IFN-gamma, and IL-12p40) and Th2 (IL-6 and IL-10) cytokines for any association with clinicopathological characteristics of epithelial ovarian cancer. mRNA was isolated, and cDNA prepared from 40 samples of epithelial ovarian cancers.
  • Tumor necrosis factor-alpha (TNF-alpha) and interferon-gamma (IFN-gamma) expression levels were significantly higher in serous adenocarcinoma than in non-serous adenocarcinoma (p<0.05), but with no difference between individual cytokine mRNA expression levels and clinical stage or histological grade.
  • Log-rank testing showed that high TNF-alpha mRNA expression (p=0.033) and the diameter of largest residual lesion at initial surgery (p=0.012) significantly correlate with longer survival in advanced stage (II/III/IV) ovarian carcinomas.
  • In examining all combinations of Th1/Th2 expression values, the most significant association was between high IFN-gamma.IL-12p40/IL-6 expression levels and better prognosis in advanced stage (II/III/IV) ovarian carcinomas (p=0.004).
  • In conclusion, Th1 and Th2 cytokines might play an important role in regulating the immune reaction in epithelial ovarian cancer cells.
  • IFN-gamma.IL-12p40/IL-6 expression may be a useful prognostic molecular marker for patients with advanced ovarian cancer.
  • [MeSH-major] Neoplasms, Glandular and Epithelial / metabolism. Ovarian Neoplasms / metabolism. Th1 Cells / metabolism. Th2 Cells / metabolism
  • [MeSH-minor] Cystadenocarcinoma, Serous / genetics. Cystadenocarcinoma, Serous / metabolism. Cystadenocarcinoma, Serous / pathology. DNA, Complementary / genetics. DNA, Complementary / metabolism. Female. Humans. Interferon-gamma / genetics. Interferon-gamma / metabolism. Interleukin-10 / genetics. Interleukin-10 / metabolism. Interleukin-12 / genetics. Interleukin-12 / metabolism. Interleukin-12 Subunit p40. Interleukin-6 / genetics. Interleukin-6 / metabolism. Ovary / metabolism. Ovary / pathology. Prognosis. Protein Subunits / genetics. Protein Subunits / metabolism. RNA, Messenger / genetics. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Tumor Necrosis Factor-alpha / genetics. Tumor Necrosis Factor-alpha / metabolism

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15870936.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / DNA, Complementary; 0 / Interleukin-12 Subunit p40; 0 / Interleukin-6; 0 / Protein Subunits; 0 / RNA, Messenger; 0 / Tumor Necrosis Factor-alpha; 130068-27-8 / Interleukin-10; 187348-17-0 / Interleukin-12; 82115-62-6 / Interferon-gamma
  •  go-up   go-down


30. Tada E, Toyomura K, Nakamura H, Sasaki H, Saito T, Kaneko M, Okuma Y, Murayama T: Activation of ceramidase and ceramide kinase by vanadate via a tyrosine kinase-mediated pathway. J Pharmacol Sci; 2010;114(4):420-32
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Also we found that 1) treatment of NBD-ceramide-labeled cells (human lung adenocarcinoma A549 cells and Chinese hamster ovary cells) with Na(3)VO(4) increased the amount of NBD-C1P formed within 30 min, 2) the treatment increased production of NBD-caproic acid, a counterpart of sphingosine, by ceramidase within 2 h, 3) expression of ceramide kinase enhanced the Na(3)VO(4)-induced formation of NBD-C1P, and tyrosine kinase inhibitors (herbimycin and genistein) decreased the response, 4) the production of NBD-caproic acid in A549 cells was inhibited by genistein, and 5) the responses for 2 h after Na(3)VO(4) treatment were accompanied by a decrease in the production of NBD-sphingomyelin, not a loss of NBD-ceramide.

  • National BioResource Project. culture/stock collections - NBRP resources .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21127389.001).
  • [ISSN] 1347-8648
  • [Journal-full-title] Journal of pharmacological sciences
  • [ISO-abbreviation] J. Pharmacol. Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Ceramides; 0 / ceramide 1-phosphate; 3WHH0066W5 / Vanadates; EC 2.7.1.- / Phosphotransferases (Alcohol Group Acceptor); EC 2.7.1.138 / ceramide kinase; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 3.5.1.23 / Ceramidases; NGZ37HRE42 / Sphingosine
  •  go-up   go-down


31. Mabuchi S, Kawase C, Altomare DA, Morishige K, Sawada K, Hayashi M, Tsujimoto M, Yamoto M, Klein-Szanto AJ, Schilder RJ, Ohmichi M, Testa JR, Kimura T: mTOR is a promising therapeutic target both in cisplatin-sensitive and cisplatin-resistant clear cell carcinoma of the ovary. Clin Cancer Res; 2009 Sep 1;15(17):5404-13
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] mTOR is a promising therapeutic target both in cisplatin-sensitive and cisplatin-resistant clear cell carcinoma of the ovary.
  • PURPOSE: Mammalian target of rapamycin (mTOR) plays a central role in cell proliferation and is regarded as a promising target in cancer therapy, including for ovarian cancer.
  • This study aimed to examine the role of mTOR as a therapeutic target in clear cell carcinoma of the ovary, which is regarded as an aggressive, chemoresistant histologic subtype.
  • EXPERIMENTAL DESIGN: Using tissue microarrays of 98 primary ovarian cancers (52 clear cell carcinomas and 46 serous adenocarcinomas), the expression of phospho-mTOR was assessed by immunohistochemistry.

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. SIROLIMUS .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Med. 2004 Jun;10(6):594-601 [15156201.001]
  • [Cites] Gynecol Oncol. 2008 Sep;110(3):336-44 [18639330.001]
  • [Cites] Oncogene. 2004 Jul 29;23(34):5853-7 [15208673.001]
  • [Cites] Gynecol Oncol. 2004 Sep;94(3):643-9 [15350353.001]
  • [Cites] Cancer Res. 1987 Jan 15;47(2):414-8 [3539322.001]
  • [Cites] J Biol Chem. 1998 Feb 27;273(9):5315-22 [9478990.001]
  • [Cites] Clin Cancer Res. 2004 Nov 1;10(21):7418-26 [15534119.001]
  • [Cites] Cell. 2005 Mar 25;120(6):747-59 [15797377.001]
  • [Cites] Cancer Res. 2005 Aug 15;65(16):7052-8 [16103051.001]
  • [Cites] Mol Cancer Ther. 2005 Oct;4(10):1533-40 [16227402.001]
  • [Cites] Int J Gynecol Cancer. 2006 Jan-Feb;16(1):52-6 [16445610.001]
  • [Cites] Cancer Res. 2006 Feb 1;66(3):1500-8 [16452206.001]
  • [Cites] Gynecol Oncol. 2006 Apr;101(1):71-5 [16290000.001]
  • [Cites] Endocrinology. 2006 Apr;147(4):1761-9 [16396982.001]
  • [Cites] Br J Cancer. 2006 May 22;94(10):1369-74 [16641903.001]
  • [Cites] Gynecol Oncol. 2006 Aug;102(2):292-9 [16443261.001]
  • [Cites] Gynecol Oncol. 2006 Aug;102(2):285-91 [16516283.001]
  • [Cites] J Surg Oncol. 2006 Aug 1;94(2):138-43 [16847906.001]
  • [Cites] Int J Gynecol Cancer. 2006 Jul-Aug;16(4):1545-51 [16884363.001]
  • [Cites] Cancer. 2000 Jun 1;88(11):2584-9 [10861437.001]
  • [Cites] Cell. 2000 Oct 13;103(2):253-62 [11057898.001]
  • [Cites] Cancer Res. 2000 Nov 1;60(21):5988-94 [11085518.001]
  • [Cites] Cancer Res. 2001 Mar 1;61(5):1862-8 [11280739.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Aug 28;98(18):10314-9 [11504908.001]
  • [Cites] Nat Rev Cancer. 2002 Jul;2(7):489-501 [12094235.001]
  • [Cites] Clin Cancer Res. 2002 Jul;8(7):2448-54 [12114452.001]
  • [Cites] J Biol Chem. 2002 Sep 6;277(36):33490-500 [12087097.001]
  • [Cites] Mol Cell. 2003 Jun;11(6):1491-501 [12820963.001]
  • [Cites] J Clin Oncol. 2003 Sep 1;21(17):3194-200 [12860964.001]
  • [Cites] Gynecol Oncol. 2003 Oct;91(1):123-9 [14529671.001]
  • [Cites] Cancer Res. 2004 Jan 1;64(1):252-61 [14729632.001]
  • [Cites] Clin Cancer Res. 2004 Feb 1;10(3):1013-23 [14871980.001]
  • [Cites] J Biol Chem. 2004 May 28;279(22):23477-85 [15026414.001]
  • [Cites] Cancer Res. 2007 Mar 15;67(6):2408-13 [17363557.001]
  • [Cites] Oncogene. 2007 Mar 22;26(13):1932-40 [17001314.001]
  • [Cites] Gynecol Oncol. 2007 May;105(2):404-8 [17292461.001]
  • [Cites] Clin Cancer Res. 2007 Jul 15;13(14):4261-70 [17634556.001]
  • [Cites] J Clin Oncol. 2007 Aug 20;25(24):3621-7 [17704411.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] Autophagy. 2008 May;4(4):467-75 [18259115.001]
  • [Cites] Lancet. 2008 Aug 9;372(9637):449-56 [18653228.001]
  • [Cites] Gynecol Oncol. 2004 Jul;94(1):197-203 [15262142.001]
  • (PMID = 19690197.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA06927; United States / NCI NIH HHS / CA / CA083638-10; United States / NCI NIH HHS / CA / CA077429-02; United States / NCI NIH HHS / CA / P30 CA006927-45; United States / NCI NIH HHS / CA / CA83638; United States / NCI NIH HHS / CA / R01 CA077429; United States / NCI NIH HHS / CA / P50 CA083638-10; United States / NCI NIH HHS / CA / P50 CA083638; United States / NCI NIH HHS / CA / R01 CA077429-02; United States / NCI NIH HHS / CA / CA77429; United States / NCI NIH HHS / CA / P30 CA006927
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Immunosuppressive Agents; 9HW64Q8G6G / Everolimus; EC 2.7.- / Protein Kinases; EC 2.7.1.1 / MTOR protein, human; EC 2.7.1.1 / TOR Serine-Threonine Kinases; EC 2.7.1.1 / mTOR protein, mouse; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt; Q20Q21Q62J / Cisplatin; W36ZG6FT64 / Sirolimus
  • [Other-IDs] NLM/ NIHMS125079; NLM/ PMC2743856
  •  go-up   go-down


32. Scott H, Griffin D: Ovarian cancer complicated by invasive pulmonary aspergillus. Gynecol Oncol; 2006 Jan;100(1):216-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ovarian cancer complicated by invasive pulmonary aspergillus.
  • CASE: A 59-year-old woman developed invasive pulmonary aspergillus after surgical debulking of an advanced ovarian adenocarcinoma and initiation of adjuvant combination chemotherapy.
  • CONCLUSION: Invasive pulmonary aspergillus is rarely diagnosed in patients with solid tumors such as ovarian cancer.
  • Successful treatment of the infection relies upon prompt diagnosis and utilization of effective antifungal medications for a prolonged period of time.
  • [MeSH-major] Aspergillosis / etiology. Cystadenocarcinoma, Serous / microbiology. Lung Diseases, Fungal / etiology. Ovarian Neoplasms / microbiology

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Aspergillosis.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16169576.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


33. Tassi RA, Bignotti E, Falchetti M, Ravanini M, Calza S, Ravaggi A, Bandiera E, Facchetti F, Pecorelli S, Santin AD: Claudin-7 expression in human epithelial ovarian cancer. Int J Gynecol Cancer; 2008 Nov-Dec;18(6):1262-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Claudin-7 expression in human epithelial ovarian cancer.
  • Claudin-7 (CLDN-7) is a tight junction protein recently found highly differentially expressed in ovarian carcinoma.
  • To evaluate its potential as a novel biomarker, in this study, we quantified and compared claudin-7 expression at messenger RNA and protein level in 110 patients harboring various histologic types of epithelial ovarian carcinomas (EOC).
  • CLDN-7 transcript was found significantly overexpressed in both primary and metastatic EOCs compared to normal human ovarian surface epithelium cell lines (fold change = 111.4, P < 0.001) by reverse transcription-polymerase chain reaction.
  • At the protein level, CLDN-7 expression was found significantly higher in tumors of primary and metastatic origin when compared to normal ovaries (P < 0.001), regardless of the histologic type, the grade of differentiation, and the pathologic stage of the disease (P = 0.12).
  • CLDN-7 is significantly overexpressed in all main histologic types of EOC and in single neoplastic cells disseminated in peritoneal cavity and pleural effusions, suggesting its potential role as novel diagnostic marker in ovarian cancer.
  • Despite widespread expression of CLDN-7 in several human normal tissues, the high density of CLDN-7 molecules, their membranous localization on EOC cells, and their lack of expression on the celomic epithelium in the peritoneal cavity suggest that this target could be potentially suitable for antibody-mediated localized therapies of ovarian adenocarcinoma.
  • [MeSH-major] Gene Expression Regulation, Neoplastic / genetics. Membrane Proteins / metabolism. Ovarian Neoplasms / metabolism

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Ovarian epithelial cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18298564.001).
  • [ISSN] 1525-1438
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CLDN7 protein, human; 0 / Claudins; 0 / Membrane Proteins
  •  go-up   go-down


34. Soliman PT, Oh JC, Schmeler KM, Sun CC, Slomovitz BM, Gershenson DM, Burke TW, Lu KH: Risk factors for young premenopausal women with endometrial cancer. Obstet Gynecol; 2005 Mar;105(3):575-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Risk factors for young premenopausal women with endometrial cancer.
  • OBJECTIVE: Endometrial cancer is the most common gynecologic malignancy in the United States.
  • The mean age at diagnosis is 61 years; however, 5-30% of women are aged younger than 50 years at the time of diagnosis.
  • METHODS: We conducted a retrospective cohort study of patients with histologically confirmed endometrial cancer treated at the University of Texas, M. D.
  • Anderson Cancer Center from 1989 to 2003.
  • Clinical characteristics including age, body mass index (BMI), parity, diabetes, and personal or family history of cancer were obtained from the medical record.
  • RESULTS: Twelve percent (188/1531) of all patients with endometrial adenocarcinoma were aged younger than 50 years.
  • The mean age at diagnosis was 41 years (range 21-49 years).
  • Thirty-six patients (19%) had synchronous ovarian cancers.
  • CONCLUSION: We found that the majority of patients diagnosed with endometrial cancer at a young age were obese and nulliparous.
  • In addition, we found a high incidence of synchronous primary ovarian cancers in this cohort of young, premenopausal women.
  • [MeSH-minor] Adenocarcinoma / etiology. Adult. Body Mass Index. Female. Humans. Menstruation Disturbances / complications. Middle Aged. Neoplasms, Multiple Primary / etiology. Neoplasms, Second Primary / etiology. Obesity / complications. Parity. Polycystic Ovary Syndrome / complications. Risk Factors

  • Genetic Alliance. consumer health - Endometrial cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15738027.001).
  • [ISSN] 0029-7844
  • [Journal-full-title] Obstetrics and gynecology
  • [ISO-abbreviation] Obstet Gynecol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


35. Saito N, Hatori T, Murata N, Shibuya K, Mitsuda A, Hasegawa C, Akima M, Ikawa M, Nonaka H: A case of concomitant occurrence of struma ovarii and malignant transformation of cystic teratoma. Int J Surg Pathol; 2007 Jul;15(3):318-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A 77-year-old woman received a total abdominal hysterectomy and bilateral salpingo-oophorectomy because of a tumor in the left ovary.
  • The tumorous lesion of the cyst wall revealed a poorly differentiated adenocarcinoma.
  • The authors diagnosed that struma ovarii and other parats coexisted as a poorly differentiated adenocarcinoma that had arisen from a mature ovarian cystic teratoma.
  • As for the identification of the origin of adenocarcinomas arising from mature ovarian cystic teratomas, more cases need to be identified and investigated.
  • [MeSH-major] Cell Transformation, Neoplastic / pathology. Ovarian Neoplasms / pathology. Struma Ovarii / pathology. Teratoma / pathology
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adenocarcinoma / pathology. Aged. Female. Gene Expression Regulation, Neoplastic. Humans. Keratin-7 / genetics. Keratin-7 / metabolism. Maximum Tolerated Dose

  • Genetic Alliance. consumer health - Teratoma.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17652549.001).
  • [ISSN] 1066-8969
  • [Journal-full-title] International journal of surgical pathology
  • [ISO-abbreviation] Int. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Keratin-7
  •  go-up   go-down


36. Kushida Y, Haba R, Kadota K, Doi T, Ishikawa M, Hirakawa E, Kira M: Composite mucinous and granulosa cell tumor of the ovary. Pathol Int; 2005 Dec;55(12):797-801
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Composite mucinous and granulosa cell tumor of the ovary.
  • A composite mucinous and granulosa cell tumor of the ovary in a 76-year-old woman is herein reported.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Granulosa Cell Tumor / pathology. Ovarian Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16287496.001).
  • [ISSN] 1320-5463
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


37. Goodheart MJ, Rose SL, Hattermann-Zogg M, Smith BJ, De Young BR, Buller RE: BRCA2 alteration is important in clear cell carcinoma of the ovary. Clin Genet; 2009 Aug;76(2):161-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] BRCA2 alteration is important in clear cell carcinoma of the ovary.
  • BRCA2 has been shown to play a significant role in hereditary ovarian carcinoma.
  • Several cases of clear cell carcinoma (CCC) of the ovary containing BRCA2 mutations have been identified.
  • We hypothesize that sequence variants of the BRCA2 gene are common in CCC of the ovary.
  • Multiple methods were utilized to detect BRCA2 genetic alterations in a cohort of 13 ovarian CCC.
  • Only one subject carried a germline sequence variation that might alter BRCA2 function despite the fact that a family history of breast, ovarian or colon cancer was common in this population.
  • [MeSH-major] Adenocarcinoma, Clear Cell / genetics. BRCA2 Protein / genetics. Mutation / genetics. Ovarian Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19656163.001).
  • [ISSN] 1399-0004
  • [Journal-full-title] Clinical genetics
  • [ISO-abbreviation] Clin. Genet.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / BRCA2 Protein
  •  go-up   go-down


38. Bolat F, Gumurdulu D, Erkanli S, Kayaselcuk F, Zeren H, Ali Vardar M, Kuscu E: Maspin overexpression correlates with increased expression of vascular endothelial growth factors A, C, and D in human ovarian carcinoma. Pathol Res Pract; 2008;204(6):379-87
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Maspin overexpression correlates with increased expression of vascular endothelial growth factors A, C, and D in human ovarian carcinoma.
  • Few studies have compared maspin with VEGF in ovarian carcinoma.
  • Therefore, we investigated the expression and correlation of maspin, VEGFA, VEGFC, and VEGFD with the tumorigenesis of the ovary and clinicopathologic variables.
  • Using immunohistochemistry, we examined maspin, VEGFA, VEGFC, and VEGFD expression in 60 ovarian carcinoma tissues (35 serous papillary carcinomas, 18 endometrioid carcinomas, and 7 primary ovarian mucinous carcinomas).
  • Maspin, VEGFC, and VEGFD are expressed in ovarian tumors with a poor prognostic parameters, and seem to play a role in ovarian cancer angiogenesis, progression, and lymph node metastases.
  • Our results indicate that in contrast to most other carcinomas, maspin expression is directly associated with the biological aggressiveness of ovarian carcinoma.
  • These results may offer new insights regarding the role of maspin in ovarian cancer and might also affect the diagnosis and treatment strategies.
  • [MeSH-major] Adenocarcinoma / metabolism. Ovarian Neoplasms / metabolism. Serpins / metabolism. Vascular Endothelial Growth Factor A / metabolism. Vascular Endothelial Growth Factor C / metabolism. Vascular Endothelial Growth Factor D / metabolism
  • [MeSH-minor] Adolescent. Adult. Aged. Biomarkers, Tumor / metabolism. Female. Humans. Lymph Nodes / metabolism. Lymph Nodes / pathology. Lymphatic Metastasis. Middle Aged. Neoplasm Staging. Ovary / metabolism. Ovary / pathology. Prognosis. Survival Rate

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18343598.001).
  • [ISSN] 0344-0338
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / SERPIN-B5; 0 / Serpins; 0 / VEGFA protein, human; 0 / VEGFC protein, human; 0 / Vascular Endothelial Growth Factor A; 0 / Vascular Endothelial Growth Factor C; 0 / Vascular Endothelial Growth Factor D
  •  go-up   go-down


39. Ozbey C, Erdogan G, Pestereli HE, Simsek T, Karaveli S: Serous papillary adenocarcinoma and adult granulosa cell tumor in the same ovary. An unusual case. APMIS; 2005 Oct;113(10):713-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Serous papillary adenocarcinoma and adult granulosa cell tumor in the same ovary. An unusual case.
  • Surface epithelial-stromal cell tumors are the most common neoplasms of the ovary but occurrence of a serous adenocarcinoma and an adult granulosa cell tumor in the same ovary is an unusual incident.
  • In the present case report we describe this very uncommon occurrence in the ovary of a 50-year-old woman.
  • Microscopy revealed an adult granulosa cell tumor and a serous papillary adenocarcinoma in the left ovary.
  • Immunohistochemical staining with inhibin alpha and pancytokeratin confirmed the diagnosis.
  • [MeSH-major] Cystadenocarcinoma, Serous / pathology. Granulosa Cell Tumor / pathology. Ovarian Neoplasms / pathology. Ovary / pathology

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] APMIS. 2007 Jun;115(6):769-71 [17550386.001]
  • (PMID = 16309432.001).
  • [ISSN] 0903-4641
  • [Journal-full-title] APMIS : acta pathologica, microbiologica, et immunologica Scandinavica
  • [ISO-abbreviation] APMIS
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / inhibin-alpha subunit; 57285-09-3 / Inhibins; 68238-35-7 / Keratins
  •  go-up   go-down


40. Silva RG, Dahmoush L, Gerke H: Pancreatic metastasis of an ovarian malignant mixed Mullerian tumor identified by EUS-guided fine needle aspiration and Trucut needle biopsy. JOP; 2006;7(1):66-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pancreatic metastasis of an ovarian malignant mixed Mullerian tumor identified by EUS-guided fine needle aspiration and Trucut needle biopsy.
  • CONTEXT: Malignant mixed Mullerian tumors are rare ovarian neoplasms that account for less than 2% of ovarian malignancies.
  • CASE REPORT: We describe a 69-year-old female with concomitant Duke's C adenocarcinoma of the colon and stage III-C malignant mixed Mullerian tumor that presented with malignant ascites, increasing abdominal girth and a pancreatic head mass.
  • The tumor was morphologically identical to the surgical specimen of her ovarian mass.
  • Although ovarian adenocarcinoma has been reported as a primary site of pancreatic metastasis, it has not been previously described originating from a mixed Mullerian tumor of the ovary presenting as a cystic pancreatic head mass.
  • [MeSH-major] Mixed Tumor, Mullerian / secondary. Ovarian Neoplasms / pathology. Pancreatic Neoplasms / secondary


41. Dhakal HP, Pradhan M: Histological pattern of gynecological cancers. JNMA J Nepal Med Assoc; 2009 Oct-Dec;48(176):301-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • INTRODUCTION: The information on cancer incidence is an important basis to prioritize the preventive policy of a country.
  • METHODS: A retrospective analysis was performed in histopathologically proven gynecological malignancies by retrieving data from the archives of the Department of Pathology, BP Koirala Memorial Cancer Hospital between July 1999 and April 2004.
  • RESULTS: Out of total 1517 cases of gynecological cancers diagnosed, 1293 cases (85.23%) were cervical, 97 (6.39%) ovarian, 48 (3.16%) vulval, 41 (2.7%) vaginal, 32 (2.11%) endometrial cancers as well as 5 (0.33%) choriocarcinoma and 1 (0.07%) fallopian tube cancer.
  • Squamous cell carcinoma was the commonest histologic type in cervical, vaginal and vulval cancers whereas serous adenocarcinoma and endometrioid adenocarcinoma were commonest histological types in the ovary and endometrium respectively.
  • CONCLUSIONS: Cervical cancer is the most frequent gynecological malignancy in Nepal.
  • Since it is a preventable disease, national screening and awareness programs are necessary to reduce the burden of the cancer and to improve the health of women in Nepal.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21105554.001).
  • [ISSN] 0028-2715
  • [Journal-full-title] JNMA; journal of the Nepal Medical Association
  • [ISO-abbreviation] JNMA J Nepal Med Assoc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Nepal
  •  go-up   go-down


42. Jiang J, Chen W, Zhuang R, Song T, Li P: The effect of endostatin mediated by human mesenchymal stem cells on ovarian cancer cells in vitro. J Cancer Res Clin Oncol; 2010 Jun;136(6):873-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The effect of endostatin mediated by human mesenchymal stem cells on ovarian cancer cells in vitro.
  • To investigate the impact of secreted endostatin on cancer cells, SKOV3 cells were co-cultured with MSC-EN cells in Millicell for 48 h, then apoptosis and cell cycle were analyzed on a flow cytometer.
  • CONCLUSION: We found that MSCs possessed great migratory capacity in vitro and the human ovarian adenocarcinoma cell line SKOV3 could significantly induce the migration of MSCs.
  • [MeSH-major] Adenocarcinoma / therapy. Angiogenesis Inhibitors / pharmacology. Apoptosis / drug effects. Endostatins / pharmacology. Genetic Therapy / methods. Mesenchymal Stromal Cells. Ovarian Neoplasms / therapy

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Genes and Gene Therapy.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Oncol. 2004 Nov;25(5):1267-71 [15492814.001]
  • [Cites] J Clin Oncol. 2002 Sep 15;20(18):3792-803 [12228199.001]
  • [Cites] Nat Med. 2004 Aug;10(8):858-64 [15235597.001]
  • [Cites] Acta Oncol. 2004;43(2):175-81 [15163166.001]
  • [Cites] Science. 2003 Jul 25;301(5632):452-4 [12881543.001]
  • [Cites] Cancer Biol Ther. 2003 Jan-Feb;2(1):48-52 [12673115.001]
  • [Cites] Blood. 2004 Mar 1;103(5):1669-75 [14576065.001]
  • [Cites] Ann Surg Oncol. 2008 Dec;15(12):3601-8 [18818971.001]
  • [Cites] Int J Hematol. 2007 Jul;86(1):8-16 [17675260.001]
  • [Cites] FASEB J. 2007 Oct;21(12):3153-61 [17513560.001]
  • [Cites] Nat Med. 2003 Jun;9(6):702-12 [12778169.001]
  • [Cites] Cancer Res. 2002 Jul 1;62(13):3603-8 [12097260.001]
  • [Cites] Am J Pathol. 2004 May;164(5):1511-8 [15111296.001]
  • [Cites] Gene Ther. 2005 Jan;12(1):30-8 [15550927.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Sep 30;100 Suppl 1:11917-23 [13679583.001]
  • [Cites] Int J Gynecol Cancer. 2000 Jan;10(S1):33-37 [11240730.001]
  • [Cites] Cell. 2000 Jan 7;100(1):57-70 [10647931.001]
  • [Cites] Chin Med J (Engl). 2005 Feb 20;118(4):296-301 [15740667.001]
  • [Cites] Cancer Res. 2006 Apr 15;66(8):4319-28 [16618757.001]
  • [Cites] J Neurosci Res. 2000 Aug 15;61(4):364-70 [10931522.001]
  • [Cites] Semin Oncol. 2006 Dec;33(6 Suppl 12):S25-6 [17223447.001]
  • [Cites] APMIS. 2004 Jul-Aug;112(7-8):496-507 [15563312.001]
  • [Cites] J Cell Sci. 2005 Oct 1;118(Pt 19):4343-52 [16144866.001]
  • [Cites] Int J Exp Pathol. 2002 Dec;83(6):265-74 [12657135.001]
  • [Cites] Exp Cell Res. 2006 Mar 10;312(5):594-607 [16376330.001]
  • [Cites] APMIS. 2003 Nov;111(11):1011-8 [14629267.001]
  • [Cites] J Clin Oncol. 2002 Sep 15;20(18):3772-84 [12228197.001]
  • [Cites] Cancer Res. 2001 Oct 15;61(20):7669-74 [11606410.001]
  • [Cites] Cancer Res. 2005 May 15;65(10):3967-79 [15899784.001]
  • [Cites] Cell. 1997 Jan 24;88(2):277-85 [9008168.001]
  • [Cites] Hematology. 2002 Apr;7(2):113-7 [12186702.001]
  • [Cites] Clin Cancer Res. 2004 Mar 1;10(5):1835-42 [15014038.001]
  • [Cites] Leukemia. 2005 Jul;19(7):1118-27 [15902288.001]
  • [Cites] Circulation. 2002 Jan 1;105(1):93-8 [11772882.001]
  • [Cites] Blood. 2001 Oct 15;98(8):2396-402 [11588036.001]
  • [Cites] Semin Oncol. 2002 Dec;29(6 Suppl 16):15-8 [12516034.001]
  • [Cites] Mol Cancer Ther. 2006 May;5(5):1290-8 [16731762.001]
  • [Cites] Clin Cancer Res. 2005 Feb 1;11(3):1259-67 [15709197.001]
  • [Cites] J Natl Cancer Inst. 2004 Nov 3;96(21):1593-603 [15523088.001]
  • [Cites] Cancer Res. 2007 Jun 15;67(12):5789-97 [17575146.001]
  • [Cites] Science. 1999 Apr 2;284(5411):143-7 [10102814.001]
  • [Cites] Gynecol Obstet Invest. 2000;50(4):269-74 [11093052.001]
  • [Cites] Life Sci. 2005 Aug 5;77(12):1331-40 [15936041.001]
  • [Cites] Hum Gene Ther. 2003 Jul 1;14(10):997-1008 [12869217.001]
  • [Cites] Cancer Res. 2005 Apr 15;65(8):3307-18 [15833864.001]
  • [Cites] J Orthop Sci. 2007 Nov;12(6):562-7 [18040639.001]
  • [Cites] Adv Cancer Res. 2005;94:197-229 [16096002.001]
  • (PMID = 19921255.001).
  • [ISSN] 1432-1335
  • [Journal-full-title] Journal of cancer research and clinical oncology
  • [ISO-abbreviation] J. Cancer Res. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Endostatins
  •  go-up   go-down


43. Yu KJ, Lee HE, Ho HC, Lee JC, Chang JW, Hong HS, Yang CH: Carcinoma erysipelatoides from squamous cell carcinoma of unknown origin. Int J Clin Pract; 2005 Sep;59(9):1104-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • It is frequently observed in patients with breast carcinoma as well as adenocarcinoma of pancreas, rectum, lung, ovary and parotid gland.

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16115190.001).
  • [ISSN] 1368-5031
  • [Journal-full-title] International journal of clinical practice
  • [ISO-abbreviation] Int. J. Clin. Pract.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 13
  •  go-up   go-down


44. Liscovitch M, Ravid D: A case study in misidentification of cancer cell lines: MCF-7/AdrR cells (re-designated NCI/ADR-RES) are derived from OVCAR-8 human ovarian carcinoma cells. Cancer Lett; 2007 Jan 8;245(1-2):350-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case study in misidentification of cancer cell lines: MCF-7/AdrR cells (re-designated NCI/ADR-RES) are derived from OVCAR-8 human ovarian carcinoma cells.
  • Multidrug-resistant MCF-7 breast adenocarcinoma cells (originally named MCF-7/AdrR cells and later re-designated NCI/ADR-RES) have served as an important and widely used research tool during the last two decades.
  • The results of these analyses, recently posted on the Web, show that NCI/ADR-RES cells are derived from OVCAR-8 ovarian adenocarcinoma cells.
  • [MeSH-minor] Adenocarcinoma / genetics. Adenocarcinoma / pathology. Antibiotics, Antineoplastic / pharmacology. Cell Line, Tumor. Clone Cells / metabolism. Female. Gene Expression Profiling. Humans. Mutation. Ovarian Neoplasms / genetics. Ovarian Neoplasms / pathology. Tumor Suppressor Protein p53 / genetics


45. Misir A, Sur M: Sertoliform endometrioid carcinoma of the ovary: a potential diagnostic pitfall. Arch Pathol Lab Med; 2007 Jun;131(6):979-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sertoliform endometrioid carcinoma of the ovary: a potential diagnostic pitfall.
  • Sertoliform endometrioid carcinoma of the ovary (SEC) is an uncommon variant that bears histologic similarity to Sertoli and Sertoli-Leydig cell tumors (SLTs).
  • Based on the clinicopathologic behavior of this entity, SEC should be considered a well-differentiated carcinoma with relatively good prognosis if limited to the ovary.
  • [MeSH-major] Carcinoma, Endometrioid / pathology. Diagnostic Errors / prevention & control. Ovarian Neoplasms / pathology. Sertoli Cell Tumor / pathology
  • [MeSH-minor] Adenocarcinoma, Mucinous / diagnosis. Adult. Aged. Carcinoid Tumor / diagnosis. Combined Modality Therapy. Diagnosis, Differential. Female. Humans. Krukenberg Tumor / diagnosis. Middle Aged

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17550331.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


46. Voglmayr E, Widder J: [Who makes decisions--the dilemma of decision-making within the framework of job-sharing in a hospital]. Wien Med Wochenschr; 2006 May;156(9-10):314-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The patient was receiving immunosuppressive therapy after kidney transplantation and then suffered from a carcinomatous ovary.
  • [MeSH-major] Adenocarcinoma / secondary. Adenocarcinoma / therapy. Communication. Decision Making. Endometrial Neoplasms / therapy. Interprofessional Relations. Neoplasms, Multiple Primary / therapy. Ovarian Neoplasms / therapy. Palliative Care / methods. Patient Care Team. Urinary Bladder Neoplasms / secondary. Urinary Bladder Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • MedlinePlus Health Information. consumer health - Palliative Care.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Med Health Care Philos. 2003;6(3):235-46 [14620460.001]
  • (PMID = 16830254.001).
  • [ISSN] 0043-5341
  • [Journal-full-title] Wiener medizinische Wochenschrift (1946)
  • [ISO-abbreviation] Wien Med Wochenschr
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Austria
  • [Chemical-registry-number] 0 / Analgesics, Opioid
  •  go-up   go-down


47. Christie DR, Shaikh FM, Lucas JA 4th, Lucas JA 3rd, Bellis SL: ST6Gal-I expression in ovarian cancer cells promotes an invasive phenotype by altering integrin glycosylation and function. J Ovarian Res; 2008 Oct 01;1(1):3
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] ST6Gal-I expression in ovarian cancer cells promotes an invasive phenotype by altering integrin glycosylation and function.
  • BACKGROUND: Ovarian adenocarcinoma is not generally discovered in patients until there has been widespread intraperitoneal dissemination, which is why ovarian cancer is the deadliest gynecologic malignancy.
  • Our laboratory has previously shown that the Golgi glycosyltransferase, ST6Gal-I, mediates the hypersialylation of beta1 integrins in colon adenocarcinoma, which leads to a more metastatic tumor cell phenotype.
  • Interestingly, ST6Gal-I mRNA is known to be upregulated in metastatic ovarian cancer, therefore the goal of the present study was to determine whether ST6Gal-I confers a similarly aggressive phenotype to ovarian tumor cells.
  • METHODS: Three ovarian carcinoma cell lines were screened for ST6Gal-I expression, and two of these, PA-1 and SKOV3, were found to produce ST6Gal-I protein.
  • CONCLUSION: ST6Gal-I mediated sialylation of beta1 integrins in ovarian cancer cells may contribute to peritoneal metastasis by altering tumor cell adhesion and migration through extracellular matrix.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncology. 2005;69(5):436-44 [16319516.001]
  • [Cites] Clin Exp Metastasis. 2000;18(1):67-75 [11206841.001]
  • [Cites] Clin Exp Metastasis. 2004;21(8):685-97 [16035613.001]
  • [Cites] Cancer Res. 2005 Jun 1;65(11):4645-52 [15930282.001]
  • [Cites] Glycobiology. 1999 Oct;9(10):1003-8 [10521536.001]
  • [Cites] Cancer Res. 1998 May 15;58(10):2253-9 [9605774.001]
  • [Cites] Gynecol Oncol. 1999 Jun;73(3):362-7 [10366461.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 May 11;96(10):5722-7 [10318951.001]
  • [Cites] Am J Pathol. 1999 May;154(5):1525-37 [10329605.001]
  • [Cites] Int J Cancer. 1999 Apr 12;81(2):243-7 [10188726.001]
  • [Cites] Oncology. 1999;56(2):89-96 [9949292.001]
  • [Cites] Cancer Res. 1998 Sep 15;58(18):4066-70 [9751611.001]
  • [Cites] Eur Arch Otorhinolaryngol. 1997;254(9-10):437-41 [9438113.001]
  • [Cites] Biochim Biophys Acta. 1998 Jan 8;1379(1):23-8 [9468328.001]
  • [Cites] Cancer Res. 1997 Oct 1;57(19):4249-56 [9331085.001]
  • [Cites] FEBS Lett. 1997 Jun 16;409(3):347-50 [9224687.001]
  • [Cites] Int J Cancer. 1996 Sep 17;67(6):826-30 [8824555.001]
  • [Cites] J Biol Chem. 1994 Apr 8;269(14):10637-43 [8144653.001]
  • [Cites] Eur J Biochem. 1993 Jan 15;211(1-2):135-40 [7678804.001]
  • [Cites] Glycobiology. 1992 Feb;2(1):49-56 [1550989.001]
  • [Cites] J Biol Chem. 1990 Oct 15;265(29):17849-53 [2211665.001]
  • [Cites] Br J Cancer. 1991 Oct;64(4):617-20 [1911209.001]
  • [Cites] Eur J Biochem. 2004 Sep;271(18):3623-34 [15355339.001]
  • [Cites] Biochim Biophys Acta. 2004 May 27;1663(1-2):52-60 [15157607.001]
  • [Cites] Oncogene. 2003 Oct 16;22(46):7137-45 [14562042.001]
  • [Cites] Hybridoma. 2000 Aug;19(4):281-6 [11001400.001]
  • [Cites] Mol Cell Biol Res Commun. 2000 Jan;3(1):48-52 [10683317.001]
  • [Cites] Glycobiology. 2007 Dec;17(12):1344-56 [17884841.001]
  • [Cites] Lab Invest. 2007 Sep;87(9):851-7 [17632542.001]
  • [Cites] J Cell Biol. 2006 Mar 27;172(7):973-81 [16567498.001]
  • [Cites] Clin Cancer Res. 2006 Jan 15;12(2):369-75 [16428474.001]
  • [Cites] World J Gastroenterol. 2005 Nov 14;11(42):6701-6 [16425369.001]
  • [Cites] Gynecol Oncol. 2003 Jun;89(3):395-401 [12798701.001]
  • [Cites] Clin Exp Metastasis. 2003;20(2):143-52 [12705635.001]
  • [Cites] Med Res Rev. 2003 Jan;23(1):32-47 [12424752.001]
  • [Cites] J Biol Chem. 2002 Sep 6;277(36):32830-6 [12091385.001]
  • [Cites] Exp Cell Res. 2002 May 15;276(1):101-10 [11978012.001]
  • [Cites] Am J Pathol. 2001 Dec;159(6):2071-80 [11733357.001]
  • [Cites] Biochim Biophys Acta. 2001 May 31;1536(2-3):148-60 [11406350.001]
  • [Cites] Glycoconj J. 2000 Oct;17(10):669-76 [11425186.001]
  • [Cites] Gynecol Oncol. 2005 Dec;99(3):631-9 [16112178.001]
  • (PMID = 19014651.001).
  • [ISSN] 1757-2215
  • [Journal-full-title] Journal of ovarian research
  • [ISO-abbreviation] J Ovarian Res
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA084248
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2584051
  •  go-up   go-down


48. Zhang J, Li YL, Zhou CY, Hu YT, Chen HZ: Expression of octamer-4 in serous and mucinous ovarian carcinoma. J Clin Pathol; 2010 Oct;63(10):879-83
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of octamer-4 in serous and mucinous ovarian carcinoma.
  • AIMS: To assess the expression of Oct4 in epithelial ovarian tumours.
  • METHODS: Expression of Oct4 was evaluated by immunohistochemistry in 460 cases of various epithelial ovarian lesions as well as 35 cases of normal fallopian tube epithelium.
  • RESULTS: Oct4 expression was significantly increased from normal epithelium (both ovarian epithelium and fallopian tube epithelium) to benign and borderline cystadenoma to carcinoma in the serous lesion subgroup.
  • Oct4 overexpression was associated with more advanced FIGO stage and higher histological grade in serous adenocarcinoma.
  • Conversely, Oct4 expression did not differ among mucinous lesions or correlate with clinicopathological parameters in patients with mucinous adenocarcinoma.
  • CONCLUSION: Results suggest that Oct4 expression may contribute to the initiation, promotion and progression of serous ovarian carcinoma; it might be a useful biomarker for the diagnosis and outcome prediction of serous ovarian carcinoma.
  • [MeSH-major] Adenocarcinoma / metabolism. Biomarkers, Tumor / metabolism. Cystadenoma / metabolism. Octamer Transcription Factor-3 / metabolism. Ovarian Neoplasms / metabolism
  • [MeSH-minor] Adenocarcinoma, Mucinous / metabolism. Adenocarcinoma, Mucinous / pathology. Disease Progression. Epithelium / metabolism. Fallopian Tubes / metabolism. Female. Humans. Neoplasm Proteins / metabolism. Neoplasm Staging. Ovary / metabolism

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20876318.001).
  • [ISSN] 1472-4146
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins; 0 / Octamer Transcription Factor-3; 0 / POU5F1 protein, human
  •  go-up   go-down


49. Schmeler KM, Tao X, Frumovitz M, Deavers MT, Sun CC, Sood AK, Brown J, Gershenson DM, Ramirez PT: Prevalence of lymph node metastasis in primary mucinous carcinoma of the ovary. Obstet Gynecol; 2010 Aug;116(2 Pt 1):269-73
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prevalence of lymph node metastasis in primary mucinous carcinoma of the ovary.
  • OBJECTIVE: To estimate the prevalence of lymph node involvement in women with primary mucinous ovarian carcinomas.
  • METHODS: A retrospective study was performed of patients with primary mucinous ovarian carcinomas evaluated at a single institution between 1985 and 2007.
  • Patients with tumors of low malignant potential and mucinous carcinomas metastatic to the ovary from other primary sites were excluded.
  • RESULTS: Patients with primary mucinous ovarian carcinomas were identified (n=107).
  • At time of surgery, 93 patients (87%) had tumors that grossly appeared to be confined to the ovary, and 14 patients (13%) had evidence of extraovarian disease.
  • Of the 93 patients with tumors that grossly appeared to be confined to the ovary at surgical exploration, 51 (55%) underwent lymphadenectomy (n=27 pelvic and paraaortic, n=19 pelvic only, n=5 paraaortic only).
  • CONCLUSION: There were no cases of isolated lymph node metastases among women with primary mucinous carcinoma grossly confined to the ovary, suggesting that routine lymphadenectomy may be omitted in these patients.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Lymph Nodes / pathology. Ovarian Neoplasms / pathology


50. Kawagishi N, Shirahata Y, Ishida K, Satoh K, Enomoto Y, Akamatsu Y, Sekiguchi S, Fukumori T, Fujimori K, Satoh A, Moriya T, Satomi S: Hepatic resection of giant metastatic tumor from clear cell carcinoma of the ovary. J Hepatobiliary Pancreat Surg; 2005;12(2):155-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hepatic resection of giant metastatic tumor from clear cell carcinoma of the ovary.
  • All cancer patients, particularly those treated for colorectal cancer, should be monitored for the presence of liver metastases, but liver metastases from ovarian clear cell carcinoma are quite rare.
  • We report a patient subjected to extended left hepatectomy due to a giant metastasis 5 years after surgical treatment for an ovarian neoplasm that was histopathologically diagnosed as clear cell carcinoma.
  • A 58-year-old woman had undergone hysterectomy and bilateral salpingo-oophorectomy due to ovarian cancer (stage Ic).
  • [MeSH-major] Adenocarcinoma, Clear Cell / pathology. Adenocarcinoma, Clear Cell / secondary. Hepatectomy. Liver Neoplasms / secondary. Liver Neoplasms / surgery. Ovarian Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15868082.001).
  • [ISSN] 0944-1166
  • [Journal-full-title] Journal of hepato-biliary-pancreatic surgery
  • [ISO-abbreviation] J Hepatobiliary Pancreat Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


51. Manjanatha MG, Shelton S, Bishop ME, Lyn-Cook LE, Aidoo A: Dietary effects of soy isoflavones daidzein and genistein on 7,12-dimethylbenz[a]anthracene-induced mammary mutagenesis and carcinogenesis in ovariectomized Big Blue transgenic rats. Carcinogenesis; 2006 Dec;27(12):2555-64
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • DMBA exposure, however, induced significant increases in the lacI MFs in the mammary of both OVX and ovary intact (INT) rats and Hprt MFs in spleen lymphocytes (P<or=0.01).
  • Although DMBA treatment did not induce mammary tumors in the OVX rats, adenoma and adenocarcinoma were detected in the mammary glands of INT rats.

  • Hazardous Substances Data Bank. GENISTEIN .
  • Hazardous Substances Data Bank. 7,12-DIMETHYLBENZ(A)ANTHRACENE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [RepublishedFrom] Carcinogenesis. 2006 Oct;27(10):1970-9 [16709578.001]
  • (PMID = 17127718.001).
  • [ISSN] 0143-3334
  • [Journal-full-title] Carcinogenesis
  • [ISO-abbreviation] Carcinogenesis
  • [Language] eng
  • [Publication-type] Corrected and Republished Article; Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Isoflavones; 0 / Phytoestrogens; 57-97-6 / 9,10-Dimethyl-1,2-benzanthracene; 6287WC5J2L / daidzein; DH2M523P0H / Genistein
  •  go-up   go-down


52. Mazziotta RM, Borczuk AC, Powell CA, Mansukhani M: CDX2 immunostaining as a gastrointestinal marker: expression in lung carcinomas is a potential pitfall. Appl Immunohistochem Mol Morphol; 2005 Mar;13(1):55-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Paraffin-embedded sections of various adenocarcinomas (13 colonic, 11 mucinous ovarian, 5 serous ovarian, 8 pancreatic, 6 ampullary, 12 gastric, 5 esophageal, 10 endometrial, 29 breast, and 55 lung) and 29 additional lung carcinomas (nonadenocarcinomas) were immunostained with antibodies to CDX2 protein, cytokeratin 7 (CK7), and cytokeratin 20 (CK20).
  • All colorectal and most ovarian mucinous carcinomas were strongly and diffusely immunoreactive for CDX2.
  • All breast, nonmucinous ovarian, and most endometrial and pancreatic adenocarcinomas showed no immunoreactivity for CDX2.
  • The authors conclude that CDX2 is a relatively specific marker for tumors with intestinal differentiation, with the caveat that its expression can be seen in primary large cell and adenocarcinomas of the lung and mucinous carcinomas of the ovary.

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Appl Immunohistochem Mol Morphol. 2006 Jun;14(2):249-50 [16785799.001]
  • (PMID = 15722794.001).
  • [ISSN] 1541-2016
  • [Journal-full-title] Applied immunohistochemistry & molecular morphology : AIMM
  • [ISO-abbreviation] Appl. Immunohistochem. Mol. Morphol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CDX2 protein, human; 0 / Homeodomain Proteins; 0 / Intermediate Filament Proteins; 0 / KRT20 protein, human; 0 / KRT7 protein, human; 0 / Keratin-20; 0 / Keratin-7; 68238-35-7 / Keratins
  •  go-up   go-down


53. Marcos Sánchez F, Sánchez Díaz E, Marrupe González D, Albo Castaño MI, Viana Alonso A, Juárez Ucelay F: [Carcinoma of the Fallopian tube: a case]. An Med Interna; 2006 Feb;23(2):83-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Transvaginal echography showed a 3-cavity cyst in right ovary.
  • Pathological study showed proliferative endometrium, bilateral follicular cysts and well differentiated serous adenocarcinoma located at fallopian tube.
  • [MeSH-major] Fallopian Tube Neoplasms / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16566658.001).
  • [ISSN] 0212-7199
  • [Journal-full-title] Anales de medicina interna (Madrid, Spain : 1984)
  • [ISO-abbreviation] An Med Interna
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


54. de França Neto AH, Rogatto S, Do Amorim MM, Tamanaha S, Aoki T, Aldrighi JM: Oncological repercussions of polycystic ovary syndrome. Gynecol Endocrinol; 2010 Oct;26(10):708-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oncological repercussions of polycystic ovary syndrome.
  • Polycystic ovary syndrome (PCOS) is a highly prevalent endocrine disorder that has been associated with insulin resistance and metabolic syndrome.
  • Evidence has suggested that PCOS may be associated with the appearance of certain types of cancer, particularly endometrial, ovarian and breast cancer.
  • [MeSH-major] Adenocarcinoma / etiology. Endometrial Neoplasms / etiology. Polycystic Ovary Syndrome / complications
  • [MeSH-minor] Breast Neoplasms / etiology. Female. Humans. Ovarian Neoplasms / etiology

  • MedlinePlus Health Information. consumer health - Polycystic Ovary Syndrome.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20528205.001).
  • [ISSN] 1473-0766
  • [Journal-full-title] Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology
  • [ISO-abbreviation] Gynecol. Endocrinol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  •  go-up   go-down


55. Devalapally H, Duan Z, Seiden MV, Amiji MM: Paclitaxel and ceramide co-administration in biodegradable polymeric nanoparticulate delivery system to overcome drug resistance in ovarian cancer. Int J Cancer; 2007 Oct 15;121(8):1830-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Paclitaxel and ceramide co-administration in biodegradable polymeric nanoparticulate delivery system to overcome drug resistance in ovarian cancer.
  • Subcutaneous sensitive (wild-type) and multidrug resistant (MDR-1 positive) SKOV-3 human ovarian adenocarcinoma xenografts were established in female Nu/Nu mice.
  • The results of this study show that combination of PTX and CER in biodegradable polymeric nanoparticles can serve as a very effective therapeutic strategy to overcome drug resistance in ovarian cancer.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Agents, Phytogenic / administration & dosage. Ceramides / administration & dosage. Drug Resistance, Neoplasm. Nanoparticles. Ovarian Neoplasms / drug therapy. Paclitaxel / administration & dosage. Polyesters

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 Wiley-Liss, Inc.
  • (PMID = 17557285.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01-CA119617
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Biocompatible Materials; 0 / Ceramides; 0 / N-(alpha-hydroxyoctadecanoyl)phytosphingosine; 0 / Polyesters; 0 / polyethylene oxide-polycaprolactone copolymer; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


56. Brown JV 3rd, Rettenmaier MA, Lopez KL, Graham C, Micha JP, Goldstein B: A phase II, multicenter trial of weekly topotecan in patients with recurrent platinum-sensitive epithelial cancers of the ovary and peritoneum. Int J Gynecol Cancer; 2008 Mar-Apr;18(2):249-54
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II, multicenter trial of weekly topotecan in patients with recurrent platinum-sensitive epithelial cancers of the ovary and peritoneum.
  • The purpose of this study was to evaluate the response rate and toxicity of weekly topotecan in patients with recurrent platinum-sensitive epithelial cancers of the ovary and peritoneum.
  • Thirty-nine platinum-sensitive recurrent ovarian cancer patients received topotecan (4 mg/m(2)) intravenously day 1, day 8, day 15, every 28 days.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Agents / administration & dosage. Neoplasm Recurrence, Local / drug therapy. Ovarian Neoplasms / drug therapy. Peritoneal Neoplasms / drug therapy. Topotecan / administration & dosage

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. Topotecan .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18334007.001).
  • [ISSN] 1525-1438
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 7M7YKX2N15 / Topotecan
  •  go-up   go-down


57. Sato KT, Lewandowski RJ, Mulcahy MF, Atassi B, Ryu RK, Gates VL, Nemcek AA Jr, Barakat O, Benson A 3rd, Mandal R, Talamonti M, Wong CY, Miller FH, Newman SB, Shaw JM, Thurston KG, Omary RA, Salem R: Unresectable chemorefractory liver metastases: radioembolization with 90Y microspheres--safety, efficacy, and survival. Radiology; 2008 May;247(2):507-15
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Primary sites (origins) included colon, breast, neuroendocrine, pancreas, lung, cholangiocarcinoma, melanoma, renal, esophageal, ovary, adenocarcinoma of unknown primary, lymphoma, gastric, duodenal, bladder, angiosarcoma, squamous cell carcinoma, thyroid, adrenal, and parotid.

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) RSNA, 2008.
  • (PMID = 18349311.001).
  • [ISSN] 1527-1315
  • [Journal-full-title] Radiology
  • [ISO-abbreviation] Radiology
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00532740
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Yttrium Radioisotopes
  •  go-up   go-down


58. Kajiyama H, Hosono S, Terauchi M, Shibata K, Ino K, Yamamoto E, Nomura S, Nawa A, Kikkawa F: Twist expression predicts poor clinical outcome of patients with clear cell carcinoma of the ovary. Oncology; 2006;71(5-6):394-401
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Twist expression predicts poor clinical outcome of patients with clear cell carcinoma of the ovary.
  • We examined the distribution and expression of this molecule in clear cell carcinoma of the ovary (CCC) to elucidate their clinical significance.
  • [MeSH-major] Adenocarcinoma, Clear Cell / diagnosis. Biomarkers, Tumor / biosynthesis. Ovarian Neoplasms / diagnosis. Twist Transcription Factor / biosynthesis

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 S. Karger AG, Basel.
  • (PMID = 17690559.001).
  • [ISSN] 1423-0232
  • [Journal-full-title] Oncology
  • [ISO-abbreviation] Oncology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Twist Transcription Factor
  •  go-up   go-down


59. Watanabe Y, Tsuchiya H, Sakabe T, Matsuoka S, Akechi Y, Fujimoto Y, Yamane K, Ikeda R, Nishio R, Terabayashi K, Ishii K, Gonda K, Matsumi Y, Ashla AA, Okamoto H, Takubo K, Tomita A, Hoshikawa Y, Kurimasa A, Itamochi H, Harada T, Terakawa N, Shiota G: CD437 induces apoptosis in ovarian adenocarcinoma cells via ER stress signaling. Biochem Biophys Res Commun; 2008 Feb 15;366(3):840-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CD437 induces apoptosis in ovarian adenocarcinoma cells via ER stress signaling.
  • A synthetic retinoid, CD437, has been shown to exert potent anti-tumor activity against various types of cancer cell lines, regardless of their sensitivities to natural retinoids.
  • We herein demonstrate that CD437 induces endoplasmic reticulum (ER) stress, including the up-regulation of CHOP, BIP and GADD34 mRNA through ER stress transducer (PERK and IRE1alpha) activation in an ovarian adenocarcinoma cell line, SKOV3.
  • It was also shown that CD437 induced the CHOP and GADD34 expressions in another four ovarian adenocarcinoma cell lines, indicating that CD437 functions as an ER stress inducer in these cell lines.
  • These results suggest that ER stress plays an important role in the mechanism by which CD437 induces apoptosis in ovarian adenocarcinoma cells.
  • [MeSH-major] Adenocarcinoma / metabolism. Apoptosis / drug effects. Endoplasmic Reticulum / metabolism. Ovarian Neoplasms / metabolism. Retinoids / administration & dosage. Signal Transduction / drug effects

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18082618.001).
  • [ISSN] 1090-2104
  • [Journal-full-title] Biochemical and biophysical research communications
  • [ISO-abbreviation] Biochem. Biophys. Res. Commun.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CD 437; 0 / Retinoids
  •  go-up   go-down


60. Whitworth MK, Backen AC, Clamp AR, Wilson G, McVey R, Friedl A, Rapraeger AC, David G, McGown A, Slade RJ, Gallagher JT, Jayson GC: Regulation of fibroblast growth factor-2 activity by human ovarian cancer tumor endothelium. Clin Cancer Res; 2005 Jun 15;11(12):4282-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Regulation of fibroblast growth factor-2 activity by human ovarian cancer tumor endothelium.
  • We have investigated the relationship among heparan sulfate, FGF-2, and the signal-transducing receptors in human, advanced-stage, serous ovarian adenocarcinoma.
  • This may be taken as a surrogate marker for the distribution of biologically active heparan sulfate and was distributed predominantly in endothelial cells and stroma but was absent from adenocarcinoma cells.
  • The data suggest that the entire extracellular signaling apparatus, consisting of FGF-2, biologically active heparan sulfate, and FGFRs capable of responding to FGF-2, is present in ovarian cancer endothelium, thereby highlighting the cytokine and its cognate receptor as potential targets for the antiangiogenic treatment of this disease.
  • [MeSH-major] Endothelium / pathology. Fibroblast Growth Factor 2 / metabolism. Ovarian Neoplasms / pathology

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15958608.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Protein Isoforms; 0 / RNA, Messenger; 0 / Receptors, Fibroblast Growth Factor; 0 / Sulfates; 103107-01-3 / Fibroblast Growth Factor 2; 9050-30-0 / Heparitin Sulfate; EC 2.7.10.1 / FGFR1 protein, human; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor, Fibroblast Growth Factor, Type 1; EC 3.1.3.1 / Alkaline Phosphatase
  •  go-up   go-down


61. Park JK, Lee JI, Kim DC, Jo HC, Shin JK, Lee SA, Lee JH, Paik WY: Endometrial carcinoma in a patient having 45,X Turner syndrome with gonadal mosaicism. J Obstet Gynaecol Res; 2008 Aug;34(4 Pt 2):745-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A 46-year-old single nulligravid woman with Turner syndrome phenotype, spontaneous menstruation, and well-differentiated adenocarcinoma of the endometrium was diagnosed as having the 45,X karyotype from peripheral blood, skin, buccal cells, and endometrium, which was confirmed using fluorescence in situ hybridization (FISH).
  • Analysis of the ovarian tissue using FISH confirmed 45,X/46,XX mosaicism.
  • [MeSH-major] Adenocarcinoma / complications. Endometrial Neoplasms / complications. Mosaicism. Ovary / pathology. Turner Syndrome / complications. Uterus / pathology

  • Genetic Alliance. consumer health - Turner syndrome.
  • MedlinePlus Health Information. consumer health - Turner Syndrome.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18840195.001).
  • [ISSN] 1341-8076
  • [Journal-full-title] The journal of obstetrics and gynaecology research
  • [ISO-abbreviation] J. Obstet. Gynaecol. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


62. Ohishi Y, Oda Y, Kurihara S, Kaku T, Yasunaga M, Nishimura I, Okuma E, Kobayashi H, Wake N, Tsuneyoshi M: Hobnail-like cells in serous borderline tumor do not represent concomitant incipient clear cell neoplasms. Hum Pathol; 2009 Aug;40(8):1168-75
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Hobnail-like cells, which suggest a diagnosis of clear cell carcinoma, are also focally observed in serous borderline tumor of the ovary, causing diagnostic confusion.
  • First, we carefully reviewed hematoxylin and eosin slides taken from 115 ovarian tumors diagnosed as clear cell carcinoma (73 cases), mixed adenocarcinoma containing clear cell carcinoma (5 cases), and serous borderline tumor (37 cases) to clarify the frequency of coexistence of typical clear cell carcinoma and serous borderline tumor.
  • No coexistence of clear cell carcinoma and serous borderline tumor was evident in any of the above 115 ovarian tumors.
  • [MeSH-major] Adenocarcinoma, Clear Cell / diagnosis. Cystadenocarcinoma, Serous / diagnosis. Ovarian Neoplasms / diagnosis. Precancerous Conditions / diagnosis
  • [MeSH-minor] Biomarkers, Tumor / metabolism. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Middle Aged. Nuclear Proteins / metabolism. Receptors, Estrogen / metabolism

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19368953.001).
  • [ISSN] 1532-8392
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Nuclear Proteins; 0 / Receptors, Estrogen; 0 / WTAP protein, human
  •  go-up   go-down


63. Terada T, Kawaguchi M: Primary clear cell adenocarcinoma of the peritoneum. Tohoku J Exp Med; 2005 Jul;206(3):271-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary clear cell adenocarcinoma of the peritoneum.
  • A 49-year-old Japanese woman underwent hysterectomy and bilateral salpingo-oophorectomy for endometrial endometrioid adenocarcinoma grade III, which was composed of undifferentiated carcinoma cells (98%) and tubular carcinoma cells (2%).
  • No clear cell adenocarcinoma elements were noted in this tumor.
  • The morphologies fulfilled the criteria of clear cell adenocarcinoma.
  • Our case was characterized by cyst formations and encapsulation in addition to the common histological features of clear cell adenocarcinoma of the uterus and ovary.
  • [MeSH-major] Adenocarcinoma, Clear Cell / diagnosis. Peritoneal Neoplasms / diagnosis
  • [MeSH-minor] Cell Proliferation. Cytoplasm / metabolism. Endometrial Neoplasms / metabolism. Female. Humans. Hysterectomy. Immunohistochemistry. Middle Aged. Ovary / pathology. Periodic Acid-Schiff Reaction. Spleen / metabolism. Stomach / metabolism. Uterine Neoplasms. Uterus / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15942157.001).
  • [ISSN] 0040-8727
  • [Journal-full-title] The Tohoku journal of experimental medicine
  • [ISO-abbreviation] Tohoku J. Exp. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


64. Zhao C, Florea A, Austin RM: Clinical utility of adjunctive high-risk human papillomavirus DNA testing in women with Papanicolaou test findings of atypical glandular cells. Arch Pathol Lab Med; 2010 Jan;134(1):103-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Among the 75 cases with hrHPV+ AGC results, 13 (17.3%) had cervical intraepithelial neoplasia grades 2/3, 10 (13.3%) had adenocarcinoma in situ, and 3 (4.0%) had cervical invasive adenocarcinoma, whereas for 234 women with hrHPV(-) results, 1 (0.4%) had cervical intraepithelial neoplasia grades 2/3, 1 (0.4%) had adenocarcinoma in situ, 1 each (0.4%) had cervical adenocarcinoma and ovarian carcinoma, and 8 (3.4%) had endometrial carcinoma.
  • CONCLUSIONS: Positive hrHPV AGC results were most strongly associated with cervical intraepithelial neoplasia grades 2/3 and adenocarcinoma in situ in women younger than 50 years.
  • Positive hrHPV AGC results were also present in all 3 cases of invasive cervical adenocarcinoma in women younger than 50 years.
  • Of note, hrHPV(-) AGC results were present in 10 of 13 carcinomas (76.9%) detected after AGC Pap tests, all in women 40 years or older with endometrial adenocarcinomas (n = 8), ovarian carcinoma (n = 1), and cervical adenosquamous carcinoma in a woman (n = 1) in her 50s.
  • Testing for hrHPV after AGC Pap testing was most helpful in the detection of cervical intraepithelial neoplasia grades 2/3, adenocarcinoma in situ, and invasive cervical adenocarcinomas in women younger than 50 years.
  • [MeSH-major] Adenocarcinoma / pathology. Cervical Intraepithelial Neoplasia / pathology. DNA, Viral. Papanicolaou Test. Papillomaviridae / genetics. Uterine Cervical Neoplasms / pathology. Vaginal Smears
  • [MeSH-minor] Adult. Age Factors. Aged. Aged, 80 and over. Carcinoma in Situ / pathology. Carcinoma in Situ / virology. Endometrial Neoplasms / pathology. Endometrial Neoplasms / virology. Female. Humans. Middle Aged. Ovarian Neoplasms / pathology. Ovarian Neoplasms / virology. Retrospective Studies. Risk Factors. Sensitivity and Specificity. Young Adult


65. Gontier E, Wartski M, Guinebretiere JM, Alberini JL: 18F-FDG PET/CT in a patient with lymph node metastasis from ovarian adenocarcinoma. AJR Am J Roentgenol; 2006 Sep;187(3):W285-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] 18F-FDG PET/CT in a patient with lymph node metastasis from ovarian adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / radionuclide imaging. Lymphatic Metastasis / radionuclide imaging. Ovarian Neoplasms / radionuclide imaging

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16928906.001).
  • [ISSN] 1546-3141
  • [Journal-full-title] AJR. American journal of roentgenology
  • [ISO-abbreviation] AJR Am J Roentgenol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


66. Ting AY, Kimler BF, Fabian CJ, Petroff BK: Characterization of a preclinical model of simultaneous breast and ovarian cancer progression. Carcinogenesis; 2007 Jan;28(1):130-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Characterization of a preclinical model of simultaneous breast and ovarian cancer progression.
  • Women at increased risk for breast cancer are often also at increased risk for ovarian cancer, reflecting common risk factors and intertwined etiologies for both diseases.
  • Unlike breast cancer prevention, primary ovarian cancer prevention has been impractical due to the low incidence, lack of risk and response biomarkers and difficulties in sampling ovarian tissue.
  • Challenges in the development of ovarian cancer prevention drugs, however, may be circumvented through the development of breast cancer prevention strategies that simultaneously decrease ovarian cancer.
  • In the present study, three commonly used mammary cancer carcinogen models [7,12-dimethylbenz[alpha]anthracene (DMBA), N-methyl-N-nitrosourea (MNU) and estradiol (E2)] were combined with local ovarian DMBA administration to induce progression to mammary and ovarian cancer concurrently in the rat.
  • Mammary and ovarian morphologies (measured as descriptive histology and dysplasia scores) were normal in vehicle controls.
  • Mammary hyperplasia was observed in DMBA/DMBA (mammary carcinogen/ovarian carcinogen) and MNU/DMBA-treated rats; however, ovarian preneoplastic changes were seldom observed after these treatments.
  • All E2/DMBA-treated rats had mammary hyperplasia, atypia, ductal carcinoma in situ and/or invasive adenocarcinoma, while 50% also developed preneoplastic changes in the ovary (ovarian epithelial and stromal hyperplasia and inclusion cyst formation).
  • In both the mammary gland and ovary, decreased estrogen receptor alpha expression was detected, and in the mammary gland elevated Ki-67 and cyclooxygenase-2 expressions were observed.
  • This combined breast and ovarian cancer rat model (systemic E2 treatment and local ovarian DMBA) may be useful for future dual target breast and ovarian cancer prevention studies.
  • [MeSH-major] Cocarcinogenesis. Disease Models, Animal. Mammary Neoplasms, Experimental / pathology. Ovarian Neoplasms / pathology
  • [MeSH-minor] 9,10-Dimethyl-1,2-benzanthracene / toxicity. Adenocarcinoma / chemically induced. Adenocarcinoma / pathology. Alkylating Agents / toxicity. Animals. Carcinogens / toxicity. Carcinoma, Intraductal, Noninfiltrating / chemically induced. Carcinoma, Intraductal, Noninfiltrating / pathology. Cell Proliferation / drug effects. Cells, Cultured. Cyclooxygenase 2 / metabolism. Disease Progression. Epithelium / drug effects. Estrogen Receptor alpha / metabolism. Estrogens / toxicity. Female. Hyperplasia / chemically induced. Hyperplasia / pathology. Immunoenzyme Techniques. Ki-67 Antigen / metabolism. Methylnitrosourea / toxicity. Precancerous Conditions. Rats. Rats, Inbred F344

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. 7,12-DIMETHYLBENZ(A)ANTHRACENE .
  • Hazardous Substances Data Bank. N-NITROSO-N-METHYLUREA .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16891317.001).
  • [ISSN] 0143-3334
  • [Journal-full-title] Carcinogenesis
  • [ISO-abbreviation] Carcinogenesis
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA089019
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Alkylating Agents; 0 / Carcinogens; 0 / Estrogen Receptor alpha; 0 / Estrogens; 0 / Ki-67 Antigen; 57-97-6 / 9,10-Dimethyl-1,2-benzanthracene; 684-93-5 / Methylnitrosourea; EC 1.14.99.1 / Cyclooxygenase 2
  •  go-up   go-down


67. Ulker V, Gedikbasi A, Numanoglu C, Ozluk Y, Saygi S, Gulkilik A, Salihoglu Y: Mucinous adenocarcinoma arising in ovarian mature cystic teratoma in pregnancy. Arch Gynecol Obstet; 2009 Aug;280(2):287-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mucinous adenocarcinoma arising in ovarian mature cystic teratoma in pregnancy.
  • We report a case of mucinous adenocarcinoma arising from mature cystic teratoma (MCT) of the ovary ascertained incidentally during pregnancy.
  • An ovarian adnexal mass was seen in a 38-year-old pregnant woman during cesarean section.
  • Oophorectomy revealed a mucinous adenocarcinoma arising from MCT with additional capsule invasion.
  • To our knowledge, this is a case of mucinous adenocarcinoma arising from MCT and the third case of malignant transformation from MCT in pregnancy in English literature.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Ovarian Neoplasms / pathology. Pregnancy Complications, Neoplastic / pathology. Teratoma / pathology


68. Huang YD, Hung YC, Yeh LS, Chiang IP, Zeng GC, Chang WC: Synchronous ovarian endometrioid adenocarcinoma and endocervical mucinous adenocarcinoma. Taiwan J Obstet Gynecol; 2006 Sep;45(3):264-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Synchronous ovarian endometrioid adenocarcinoma and endocervical mucinous adenocarcinoma.
  • OBJECTIVE: We report a rare case of synchronous cancer consisting of ovarian endometrioid adenocarcinoma and endocervical mucinous adenocarcinoma.
  • Histology showed moderately to poorly differentiated endometrioid adenocarcinoma of the right ovary with extensive lymphovascular permeation, as well as paraaortic and bilateral pelvic lymph node metastases.
  • Extensive tumor thrombi were observed in the lymphovascular channels of the left ovary, bilateral tubes and uterus.
  • Endocervical adenocarcinoma, < 3 mm in depth, was also identified on the cervix.
  • The final surgical-pathologic stage of ovarian endometrioid adenocarcinoma was stage IIIc and of endocervical mucinous adenocarcinoma was stage IA1.
  • CONCLUSION: The coexistence of primary neoplasms in the ovary and cervix is rare.
  • Diagnosis should be based on histologic examination and requires appropriate treatment for both tumors.
  • [MeSH-major] Adenocarcinoma, Mucinous / epidemiology. Carcinoma, Endometrioid / epidemiology. Neoplasms, Multiple Primary / pathology. Ovarian Neoplasms / epidemiology. Uterine Cervical Neoplasms / epidemiology


69. Zhang Z, Sha X, Shen A, Wang Y, Sun Z, Gu Z, Fang X: Polycation nanostructured lipid carrier, a novel nonviral vector constructed with triolein for efficient gene delivery. Biochem Biophys Res Commun; 2008 Jun 6;370(3):478-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Its in vitro gene transfer properties were evaluated in the human lung adenocarcinoma cell line SPC-A1 and Chinese Hamster Ovary (CHO) cells.

  • Hazardous Substances Data Bank. TRIOLEIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18395002.001).
  • [ISSN] 1090-2104
  • [Journal-full-title] Biochemical and biophysical research communications
  • [ISO-abbreviation] Biochem. Biophys. Res. Commun.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cations; 0 / enhanced green fluorescent protein; 122-32-7 / Triolein; 147336-22-9 / Green Fluorescent Proteins; 9002-98-6 / Polyethyleneimine
  •  go-up   go-down


70. Takano M, Yoshikawa T, Kato M, Aida S, Goto T, Furuya K, Kikuchi Y: Primary clear cell carcinoma of the peritoneum: report of two cases and a review of the literature. Eur J Gynaecol Oncol; 2009;30(5):575-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The most common neoplasms of the peritoneum are malignant mesothelioma and serous papillary adenocarcinoma.
  • Clear cell carcinoma (CCC) is mostly derived from the ovary and often associated with endometriosis.
  • The ovaries and uterine endometrium of these cases were not affected, and the tumors were diagnosed as Stage IIIc CCC of the peritoneum origin.
  • [MeSH-major] Adenocarcinoma, Clear Cell / pathology. Antineoplastic Combined Chemotherapy Protocols. Peritoneal Neoplasms / pathology

  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Eur J Gynaecol Oncol. 2010;31(1):4. Yoshokawa, T [corrected to Yoshikawa, T]
  • (PMID = 19899421.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Italy
  • [Chemical-registry-number] 7673326042 / irinotecan; Q20Q21Q62J / Cisplatin; XT3Z54Z28A / Camptothecin
  • [Number-of-references] 15
  •  go-up   go-down


71. Kurman RJ, McConnell TG: Precursors of endometrial and ovarian carcinoma. Virchows Arch; 2010 Jan;456(1):1-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Precursors of endometrial and ovarian carcinoma.
  • This review discusses precursor lesions of endometrial and ovarian carcinoma with an emphasis on the unique molecular alterations that have led to the development of binary classification schemes for tumors of both the endometrium and ovary.
  • While such a system is well established for endometrial carcinoma, only recently has a binary classification scheme been proposed for ovarian carcinoma.
  • Furthermore, similarities and differences of the precursor lesions of specific tumors of these two genital tract organs are also addressed with a brief discussion of the clinical implications of their diagnosis.
  • [MeSH-major] Endometrial Neoplasms / pathology. Ovarian Neoplasms / pathology. Precancerous Conditions / pathology
  • [MeSH-minor] Adenocarcinoma, Mucinous / pathology. Carcinoma, Endometrioid / pathology. Endometrial Hyperplasia / pathology. Female. Humans. Tumor Suppressor Protein p53 / metabolism

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gynecol Oncol. 1995 Oct;59(1):81-6 [7557621.001]
  • [Cites] Cancer Res. 1991 Oct 1;51(19):5308-14 [1913654.001]
  • [Cites] Br J Cancer. 2001 Jan;84(2):209-17 [11161379.001]
  • [Cites] Jpn J Cancer Res. 1999 Jan;90(1):55-9 [10076565.001]
  • [Cites] Cancer Res. 1998 Aug 1;58(15):3254-8 [9699651.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Jun 1;90(11):4961-5 [8506342.001]
  • [Cites] Clin Cancer Res. 2008 Apr 15;14(8):2263-9 [18369088.001]
  • [Cites] Gynecol Oncol. 1992 Jul;46(1):51-4 [1634141.001]
  • [Cites] Int J Gynecol Pathol. 2000 Oct;19(4):314-21 [11109159.001]
  • [Cites] Cancer Biol Ther. 2006 Jul;5(7):779-85 [16721043.001]
  • [Cites] Eur J Cancer. 2003 Sep;39(13):1818-27 [12932658.001]
  • [Cites] Int J Gynecol Pathol. 2008 Jan;27(1):1-9 [18156967.001]
  • [Cites] Cancer Res. 1998 May 15;58(10 ):2095-7 [9605750.001]
  • [Cites] Gynecol Oncol. 1994 Sep;54(3):264-8 [8088602.001]
  • [Cites] Int J Gynecol Pathol. 2008 Apr;27(2):151-60 [18317228.001]
  • [Cites] Int J Surg Pathol. 2004 Jul;12(3):207-23 [15306933.001]
  • [Cites] Gynecol Oncol. 1996 Feb;60(2):238-44 [8631545.001]
  • [Cites] Am J Surg Pathol. 1996 Nov;20(11):1331-45 [8898837.001]
  • [Cites] J Natl Cancer Inst. 2000 Jun 7;92 (11):924-30 [10841828.001]
  • [Cites] Cancer. 1985 Jul 15;56(2):403-12 [4005805.001]
  • [Cites] Gynecol Oncol. 2000 Apr;77(1):55-65 [10739691.001]
  • [Cites] Am J Pathol. 2004 May;164(5):1511-8 [15111296.001]
  • [Cites] Histopathology. 1995 Oct;27(4):367-71 [8847068.001]
  • [Cites] N Engl J Med. 1993 Oct 28;329(18):1318-27 [8413413.001]
  • [Cites] Am J Pathol. 1991 Oct;139(4):777-85 [1656759.001]
  • [Cites] Gynecol Oncol. 2008 May;109(2):168-73 [18342932.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Nov 10;95(23 ):13513-8 [9811831.001]
  • [Cites] Curr Opin Obstet Gynecol. 2007 Feb;19(1):3-9 [17218844.001]
  • [Cites] Am J Surg Pathol. 2006 May;30(5):614-24 [16699316.001]
  • [Cites] Hum Pathol. 2000 May;31(5):539-57 [10836293.001]
  • [Cites] Arch Pathol Lab Med. 1981 Nov;105(11):615-8 [6895302.001]
  • [Cites] Int J Gynecol Pathol. 2007 Apr;26(2):103-14 [17413975.001]
  • [Cites] Gynecol Oncol. 2006 Dec;103(3):883-7 [16806438.001]
  • [Cites] Am J Pathol. 1995 Jan;146(1):182-8 [7856726.001]
  • [Cites] Gynecol Oncol. 2003 Aug;90(2):378-81 [12893203.001]
  • [Cites] Am J Surg Pathol. 1992 Jun;16(6):600-10 [1599038.001]
  • [Cites] J Natl Cancer Inst. 1994 Aug 17;86(16):1216-21 [8040889.001]
  • [Cites] Am J Surg Pathol. 2009 Jun;33(6):844-53 [19342944.001]
  • [Cites] Int J Gynecol Pathol. 2008 Jul;27(3):318-25 [18580308.001]
  • [Cites] Anal Quant Cytol Histol. 1986 Mar;8(1):46-8 [3954843.001]
  • [Cites] Eur J Gynaecol Oncol. 2006;27(4):389-92 [17009632.001]
  • [Cites] Am J Surg Pathol. 1996 Nov;20(11):1319-30 [8898836.001]
  • [Cites] Am J Pathol. 1997 Jan;150(1):177-85 [9006334.001]
  • [Cites] Am J Pathol. 2001 Jun;158(6):1895-8 [11395362.001]
  • [Cites] Int J Gynecol Pathol. 2003 Jan;22(1):37-41 [12496696.001]
  • [Cites] J Natl Cancer Inst. 2000 Jul 5;92(13):1088-91 [10880552.001]
  • [Cites] Cancer Res. 2004 Oct 1;64(19):6915-8 [15466181.001]
  • [Cites] Int J Surg Pathol. 2004 Oct;12(4):319-31 [15494858.001]
  • [Cites] Cancer. 1998 Mar 15;82(6):1088-95 [9506354.001]
  • [Cites] J Pathol. 2004 Mar;202(3):336-40 [14991899.001]
  • [Cites] Am J Surg Pathol. 2005 Feb;29(2):218-24 [15644779.001]
  • [Cites] Cancer Res. 2000 Dec 15;60(24):7052-6 [11156411.001]
  • [Cites] Am J Obstet Gynecol. 1993 Jul;169(1):181-2 [8392791.001]
  • [Cites] J Pathol. 2006 Apr;208(5):708-13 [16429393.001]
  • [Cites] Int J Gynecol Cancer. 2008 May-Jun;18(3):487-91 [17692090.001]
  • [Cites] Histopathology. 1997 Mar;30(3):249-55 [9088954.001]
  • [Cites] Cancer Res. 2000 Mar 15;60(6):1750-2 [10749149.001]
  • [Cites] J Natl Cancer Inst. 1993 Sep 15;85(18):1513-9 [8360934.001]
  • [Cites] Gynecol Oncol. 2000 Mar;76(3):287-90 [10684697.001]
  • [Cites] Am J Surg Pathol. 2006 Feb;30(2):230-6 [16434898.001]
  • [Cites] Gynecol Oncol. 1983 Feb;15(1):10-7 [6822361.001]
  • [Cites] Cancer. 1994 Apr 1;73(7):1859-64 [8137211.001]
  • [Cites] Pathology. 1979 Jan;11(1):5-26 [431978.001]
  • [Cites] Gynecol Oncol. 1999 Sep;74(3):385-94 [10479498.001]
  • [Cites] Am J Surg Pathol. 1998 Aug;22(8):1012-9 [9706982.001]
  • [Cites] Cancer. 2000 Feb 15;88(4):814-24 [10679651.001]
  • [Cites] Am J Surg Pathol. 2005 Jun;29(6):707-23 [15897738.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] Hum Pathol. 1995 Nov;26(11):1260-7 [7590702.001]
  • [Cites] Am J Pathol. 2009 May;174(5):1597-601 [19349352.001]
  • [Cites] J Pathol. 2001 Nov;195(4):451-6 [11745677.001]
  • [Cites] Am J Pathol. 2002 Apr;160(4):1223-8 [11943707.001]
  • [Cites] Histopathology. 1981 Jan;5(1):61-8 [7216177.001]
  • [Cites] Am J Surg Pathol. 1999 Sep;23(9):1102-8 [10478671.001]
  • [Cites] Oncogene. 1994 Apr;9(4):1163-6 [8134118.001]
  • [Cites] Jpn J Cancer Res. 1998 Oct;89(10 ):985-90 [9849574.001]
  • [Cites] N Engl J Med. 1988 Sep 1;319(9):525-32 [2841597.001]
  • [Cites] Virchows Arch. 2004 Mar;444(3):213-23 [14747944.001]
  • [Cites] Am J Surg Pathol. 1982 Mar;6(2):93-108 [7102898.001]
  • [Cites] Gynecol Obstet Invest. 2000;50 Suppl 1:44-50 [11093061.001]
  • [Cites] Hum Pathol. 1995 Nov;26(11):1268-74 [7590703.001]
  • [Cites] Gynecol Oncol. 1992 Dec;47(3):298-305 [1473741.001]
  • [Cites] Cancer Res. 1994 Mar 15;54(6):1604-7 [8137266.001]
  • [Cites] Cancer Res. 1998 Jun 15;58(12 ):2500-3 [9635567.001]
  • [Cites] J Natl Cancer Inst. 2003 Mar 19;95(6):484-6 [12644542.001]
  • [Cites] Cancer. 2008 Oct 15;113(8):2073-81 [18720479.001]
  • [Cites] Am J Surg Pathol. 2006 Dec;30(12):1519-30 [17122507.001]
  • (PMID = 19859732.001).
  • [ISSN] 1432-2307
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Tumor Suppressor Protein p53
  • [Number-of-references] 88
  •  go-up   go-down


72. Othumpangat S, Kashon M, Joseph P: Sodium arsenite-induced inhibition of eukaryotic translation initiation factor 4E (eIF4E) results in cytotoxicity and cell death. Mol Cell Biochem; 2005 Nov;279(1-2):123-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Exposure to arsenic (As) is a risk factor for the development of diabetes, vascular diseases and cancer.
  • Exposure of four different human cell lines - HCT15 (colorectal adenocarcinoma), PLC/PR/5 (hepatocellular carcinoma), HeLa (cervical adenocarcinoma) and Chang (likely derived from HeLa cells) to sodium arsenite (NaAsO2) for time intervals up to 24 h resulted in a concentration-dependent cytotoxicity and cell death.
  • Overexpression of the eIF4E gene in the Chinese hamster ovary cell line was protective against the NaAsO2-induced cytotoxicity and cell death.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Environ Health Perspect. 1999 Jul;107(7):593-7 [10379007.001]
  • [Cites] Cell Cycle. 2003 Jul-Aug;2(4):358-68 [12851490.001]
  • [Cites] Toxicol Appl Pharmacol. 2001 May 1;172(3):225-32 [11312651.001]
  • [Cites] Mutat Res. 2003 Jan 10;534(1-2):133-43 [12504762.001]
  • [Cites] Cancer Res. 2000 Jul 1;60(13):3445-53 [10910055.001]
  • [Cites] Mol Cell Biol. 1988 Aug;8(8):3556-9 [3062383.001]
  • [Cites] Annu Rev Biochem. 1998;67:425-79 [9759494.001]
  • [Cites] J Cell Physiol. 2002 Jan;190(1):29-37 [11807808.001]
  • [Cites] J Biol Chem. 2004 Aug 6;279(32):33968-75 [15178684.001]
  • [Cites] J Biol Chem. 1995 Sep 8;270(36):21176-80 [7673150.001]
  • [Cites] Oncogene. 1999 Jul 29;18(30):4326-35 [10439040.001]
  • [Cites] J Toxicol Environ Health A. 2000 Jan 28;59(2):119-34 [10653439.001]
  • [Cites] J Cell Mol Med. 2001 Jul-Sep;5(3):221-39 [12067482.001]
  • [Cites] Mutat Res. 1997 Jun;386(3):219-28 [9219560.001]
  • [Cites] Cancer Res. 2004 Dec 15;64(24):8960-7 [15604259.001]
  • [Cites] Eur J Biochem. 2000 Feb;267(4):1083-91 [10672017.001]
  • [Cites] J Environ Pathol Toxicol Oncol. 2000;19(3):281-6 [10983894.001]
  • [Cites] Science. 1988 Jul 1;241(4861):79-81 [3388020.001]
  • [Cites] Toxicol Appl Pharmacol. 2003 Jan 15;186(2):101-9 [12639501.001]
  • [Cites] J Biol Chem. 2000 Aug 11;275(32):24776-80 [10811643.001]
  • [Cites] Oncogene. 2000 Jun 15;19(26):3021-31 [10871854.001]
  • [Cites] J Biol Chem. 2005 Jul 1;280(26):25162-9 [15878868.001]
  • [Cites] Mol Cell Biol. 1991 Nov;11(11):5435-45 [1922056.001]
  • [Cites] Cancer Causes Control. 1997 May;8(3):371-85 [9498900.001]
  • [Cites] Cell Death Differ. 2001 Aug;8(8):841-9 [11526437.001]
  • [Cites] Cancer Res. 1995 Mar 15;55(6):1296-300 [7882325.001]
  • [Cites] Br J Cancer. 1992 Nov;66(5):888-92 [1419632.001]
  • [Cites] Toxicol Lett. 2002 Jul 7;133(1):47-57 [12076509.001]
  • [Cites] J Biol Chem. 2001 Apr 6;276(14):11414-9 [11150309.001]
  • [Cites] Environ Health Perspect. 2000 May;108(5):393-7 [10811564.001]
  • [Cites] Am J Epidemiol. 1998 Apr 1;147(7):660-9 [9554605.001]
  • [Cites] Oncogene. 2000 Mar 9;19(11):1437-47 [10723135.001]
  • [Cites] J Biol Chem. 1985 May 10;260(9):5486-92 [3988764.001]
  • [Cites] Cancer Res. 2003 Nov 15;63(22):7950-8 [14633726.001]
  • [Cites] Toxicol Lett. 2001 Jul 6;122(3):223-34 [11489357.001]
  • [Cites] Carcinogenesis. 1985 Oct;6(10):1421-6 [3840060.001]
  • [Cites] J Toxicol Environ Health B Crit Rev. 1998 Jul-Sep;1(3):199-241 [9644328.001]
  • [Cites] Proc Natl Acad Sci U S A. 1990 Nov;87(21):8212-6 [2122455.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Feb 6;93(3):1065-70 [8577715.001]
  • [Cites] Anal Chem. 1999 Apr 1;71(7):1408-14 [10204040.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Feb 19;99(4):1990-5 [11842186.001]
  • [Cites] J Biol Chem. 2001 Aug 3;276(31):29111-5 [11408474.001]
  • [Cites] EMBO J. 1996 Nov 15;15(22):6269-79 [8947050.001]
  • [Cites] Mol Cell Biol. 1996 Nov;16(11):6573-81 [8887686.001]
  • [Cites] Mol Cell Biol. 2002 Mar;22(6):1656-63 [11865045.001]
  • [Cites] Nucleic Acids Res. 1989 Aug 11;17(15):5923-31 [2671936.001]
  • (PMID = 16283521.001).
  • [ISSN] 0300-8177
  • [Journal-full-title] Molecular and cellular biochemistry
  • [ISO-abbreviation] Mol. Cell. Biochem.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Arsenites; 0 / Eukaryotic Initiation Factor-4E; 0 / RNA, Messenger; 0 / RNA, Small Interfering; 0 / Sodium Compounds; 0 / Ubiquitin; 136601-57-5 / Cyclin D1; 48OVY2OC72 / sodium arsenite
  •  go-up   go-down


73. Sughayer MA, Zakarneh L, Abu-Shakra R: Collision metastasis of breast and ovarian adenocarcinoma in axillary lymph nodes: a case report and review of the literature. Pathol Oncol Res; 2009 Sep;15(3):423-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Collision metastasis of breast and ovarian adenocarcinoma in axillary lymph nodes: a case report and review of the literature.
  • Despite their accepted clinical and genetic association, the incidence of synchronous breast and ovarian carcinoma is rare.
  • Moreover, collision metastasis from both breast and ovarian carcinomas to the same lymph node, to our knowledge has never been reported.
  • Review of the literature revealed eleven cases of metastatic malignant tumors colliding in the same lymph node, none of which had both ovarian and breast carcinoma.
  • One month later the patient was found to have malignant ascites, omental carcinomatosis and an ovarian mass.
  • Histology and immunohistochemistry revealed high grade serous papillary adenocarcinoma.
  • When surgery was done to treat the breast tumor some of the axillary lymph nodes revealed metastases from the breast primary, others metastases from the ovarian primary and one had both tumors in a collision phenomenon.
  • [MeSH-major] Adenocarcinoma / pathology. Breast Neoplasms / pathology. Lymphatic Metastasis / pathology. Neoplasms, Multiple Primary / pathology. Ovarian Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 1996 Feb;20(2):245-50 [8554115.001]
  • [Cites] Am J Clin Pathol. 1983 Aug;80(2):228-30 [6349326.001]
  • [Cites] Pathol Int. 1996 Oct;46(10):787-90 [8916150.001]
  • [Cites] Int J Urol. 1997 Mar;4(2):222-4 [9179702.001]
  • [Cites] Dis Colon Rectum. 2005 Feb;48(2):384-9 [15812588.001]
  • [Cites] Science. 1994 Oct 7;266(5182):66-71 [7545954.001]
  • [Cites] Arch Pathol Lab Med. 2004 Mar;128(3):318-20 [14987155.001]
  • [Cites] Int Urol Nephrol. 1995;27(6):743-5 [8725040.001]
  • [Cites] Science. 1994 Sep 30;265(5181):2088-90 [8091231.001]
  • [Cites] Arch Pathol Lab Med. 2001 Oct;125(10):1354-7 [11570915.001]
  • [Cites] J Pathol. 1969 Jan;97(1):143-5 [5783628.001]
  • [Cites] Surg Radiol Anat. 1993;15(2):119-23 [7690160.001]
  • (PMID = 19067238.001).
  • [ISSN] 1532-2807
  • [Journal-full-title] Pathology oncology research : POR
  • [ISO-abbreviation] Pathol. Oncol. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / CA-125 Antigen; 0 / Carrier Proteins; 0 / Glycoproteins; 0 / PIP protein, human
  • [Number-of-references] 12
  •  go-up   go-down


74. Ohtsuki S, Kamoi M, Watanabe Y, Suzuki H, Hori S, Terasaki T: Correlation of induction of ATP binding cassette transporter A5 (ABCA5) and ABCB1 mRNAs with differentiation state of human colon tumor. Biol Pharm Bull; 2007 Jun;30(6):1144-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • ABCA5 and ABCA8 mRNAs were detected in spleen, testis and ovary.
  • ABCA5 mRNA was detected in poorly differentiated colon adenocarcinoma (GI-112) and undifferentiated ovarian carcinoma (GI-102), but not in normal colon.
  • In contrast, ABCC1 and ABCA2 mRNAs, but not ABCA5 or ABCB1 mRNA, were detected in well differentiated colon adenocarcinoma (CX-1).
  • [MeSH-major] ATP-Binding Cassette Transporters / metabolism. Adenocarcinoma / metabolism. Colonic Neoplasms / metabolism. Organic Anion Transporters / metabolism. RNA, Messenger / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17541169.001).
  • [ISSN] 0918-6158
  • [Journal-full-title] Biological & pharmaceutical bulletin
  • [ISO-abbreviation] Biol. Pharm. Bull.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / ABCA5 protein, human; 0 / ABCB1 protein, human; 0 / ATP Binding Cassette Transporter, Sub-Family B; 0 / ATP-Binding Cassette Transporters; 0 / ATP-Binding Cassette, Sub-Family B, Member 1; 0 / DNA, Complementary; 0 / Organic Anion Transporters; 0 / RNA, Messenger
  •  go-up   go-down


75. Yamano T, Morii E, Arai I, Takada T, Kubota K, Sato M, Inoue T, Okada Y, Hara T, Aozasa K: Diagnosis of primary versus metastatic ovarian adenocarcinoma using p53 gene mutation analysis. Int J Clin Oncol; 2010 Dec;15(6):621-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnosis of primary versus metastatic ovarian adenocarcinoma using p53 gene mutation analysis.
  • Distinguishing primary ovarian cancer from metastatic colorectal cancer is often difficult by a conventional pathological examination alone.
  • We assessed the usefulness of p53 gene mutation analysis for the differential diagnosis of ovarian adenocarcinoma.
  • A 66-year-old woman suffered multiple organ metastases, including the liver, para-aortic lymph node, and right ovary, following an operation for advanced sigmoid colon cancer.
  • She underwent ovarian resection after effective chemotherapy against the liver and para-aortic lymph node cancer.
  • Histological analysis suggested primary ovarian cancer.
  • Therefore, we applied p53 gene mutation analysis for the differential diagnosis of primary versus metastatic ovarian cancer from sigmoid colon cancer.
  • The direct sequence of the p53 gene demonstrated the same gene mutation in codon 211 (ACT to ATT) in both the sigmoid colon and ovarian cancers.
  • According to the International Agency for Research on Cancer TP53 mutation database, this type of p53 mutation in colorectal cancer and ovarian cancer is 0.13% (5/3,693) and 0% (0/1,494), respectively.
  • Therefore, we determined that the ovarian tumor was metastatic.
  • Although p53 gene mutation analysis has been applied in some cases, this modality is very useful for the differential diagnosis of primary and metastatic cancer.
  • [MeSH-major] Liver Neoplasms / genetics. Liver Neoplasms / secondary. Mutation / genetics. Ovarian Neoplasms / diagnosis. Ovarian Neoplasms / genetics. Tumor Suppressor Protein p53 / genetics
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adenocarcinoma / genetics. Adenocarcinoma / secondary. Aged. Colonic Neoplasms / diagnosis. Colonic Neoplasms / genetics. Diagnosis, Differential. Female. Humans. Lymphatic Metastasis

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Tumori. 2006 Nov-Dec;92(6):491-5 [17260489.001]
  • [Cites] Am J Surg Pathol. 2008 Jan;32(1):128-38 [18162780.001]
  • [Cites] Mod Pathol. 2006 Nov;19(11):1421-8 [16980943.001]
  • [Cites] Mod Pathol. 2005 Jan;18(1):19-25 [15389251.001]
  • [Cites] Obstet Gynecol. 1997 Jan;89(1):85-7 [8990444.001]
  • [Cites] Eur J Gynaecol Oncol. 2004;25(6):713-5 [15597848.001]
  • [Cites] Gynecol Oncol. 2003 May;89(2):314-7 [12713997.001]
  • [Cites] J Thorac Oncol. 2008 Aug;3(8):931-4 [18670315.001]
  • [Cites] J Clin Oncol. 2005 Oct 20;23(30):7518-28 [16172461.001]
  • [Cites] Cancer Res. 1992 Sep 15;52(18):5119-22 [1516069.001]
  • [Cites] Hum Pathol. 2002 Nov;33(11):1078-85 [12454811.001]
  • [Cites] Cancer Res. 1992 Jul 1;52(13):3674-8 [1319827.001]
  • [Cites] Clin Cancer Res. 2000 Sep;6(9):3499-504 [10999735.001]
  • [Cites] Am J Clin Pathol. 2002 Jun;117(6):944-51 [12047147.001]
  • [Cites] Biochem Biophys Res Commun. 2004 Dec 17;325(3):784-91 [15541358.001]
  • [Cites] J Clin Oncol. 2004 Apr 1;22(7):1209-14 [15051767.001]
  • [Cites] Clin Colorectal Cancer. 2004 Feb;3(4):215-22 [15025793.001]
  • [Cites] Ann Surg Oncol. 1998 Dec;5(8):695-8 [9869515.001]
  • [Cites] Diagn Mol Pathol. 1993 Mar;2(1):29-35 [8287223.001]
  • (PMID = 20514505.001).
  • [ISSN] 1437-7772
  • [Journal-full-title] International journal of clinical oncology
  • [ISO-abbreviation] Int. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / TP53 protein, human; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


76. Moschos SJ, Mo YY: Role of SUMO/Ubc9 in DNA damage repair and tumorigenesis. J Mol Histol; 2006 Sep;37(5-7):309-19
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Recent reports indicate that Ubc9, the single SUMO E2 enzyme catalyzing the conjugation of SUMO to target proteins, is overexpressed in certain tumors, such as lung adenocarcinoma, ovarian carcinoma and melanoma, suggestive of its clinic significance.

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] FEBS Lett. 2005 Sep 12;579(22):5007-12 [16122737.001]
  • [Cites] J Urol. 2006 Feb;175(2):739-43 [16407042.001]
  • [Cites] Oncogene. 2003 Aug 14;22(34):5348-57 [12917636.001]
  • [Cites] FEBS Lett. 2003 Jul 10;546(2-3):374-8 [12832072.001]
  • [Cites] Nature. 1995 Jan 5;373(6509):78-81 [7800043.001]
  • [Cites] FEBS Lett. 2004 Aug 27;573(1-3):15-8 [15327968.001]
  • [Cites] Nat Rev Mol Cell Biol. 2005 Jan;6(1):44-55 [15688066.001]
  • [Cites] Genomics. 1996 Oct 15;37(2):183-6 [8921390.001]
  • [Cites] Mol Cell. 2004 May 21;14 (4):491-500 [15149598.001]
  • [Cites] Clin Cancer Res. 2002 Apr;8(4):1127-38 [11948124.001]
  • [Cites] J Proteome Res. 2004 Nov-Dec;3(6):1191-200 [15595728.001]
  • [Cites] J Cell Biol. 2005 Dec 19;171(6):947-54 [16344309.001]
  • [Cites] J Biol Chem. 2002 Jan 25;277(4):2958-64 [11709553.001]
  • [Cites] Neoplasia. 2000 May-Jun;2(3):208-25 [10935507.001]
  • [Cites] Nature. 2003 Sep 11;425(6954):188-91 [12968183.001]
  • [Cites] Mutat Res. 2005 Sep 4;577(1-2):275-83 [15922366.001]
  • [Cites] J Biol Chem. 2005 Jun 24;280(25):23566-75 [15817450.001]
  • [Cites] Mol Cell. 2005 Sep 16;19(6):817-28 [16168376.001]
  • [Cites] J Biol Chem. 2005 Feb 18;280(7):5611-21 [15569683.001]
  • [Cites] J Biol Chem. 2001 Nov 2;276(44):40389-95 [11384992.001]
  • [Cites] Mol Cell. 2005 Apr 1;18(1):1-12 [15808504.001]
  • [Cites] Oncogene. 2005 Apr 18;24(17):2899-908 [15838523.001]
  • [Cites] Chem Res Toxicol. 2004 Dec;17 (12 ):1706-15 [15606148.001]
  • [Cites] Trends Biochem Sci. 2003 Jun;28(6):321-8 [12826404.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Nov 11;100(23):13225-30 [14578449.001]
  • [Cites] Exp Cell Res. 2002 Nov 1;280(2):212-21 [12413887.001]
  • [Cites] Mol Cell Biol. 2005 Aug;25(16):7021-32 [16055714.001]
  • [Cites] Expert Opin Ther Targets. 2005 Dec;9(6):1203-16 [16300471.001]
  • [Cites] J Cell Biol. 2003 Nov 10;163(3):477-87 [14597774.001]
  • [Cites] Mol Cell. 2006 Mar 17;21(6):837-48 [16543152.001]
  • [Cites] Nucleic Acids Res. 2000 Mar 1;28(5):1145-53 [10666456.001]
  • [Cites] Gene. 1997 May 6;190(2):287-96 [9197546.001]
  • [Cites] J Biol Chem. 2005 Feb 11;280(6):5004-12 [15561718.001]
  • [Cites] FEBS Lett. 2005 Jun 20;579(16):3369-75 [15922331.001]
  • [Cites] Oncogene. 2005 Apr 14;24(16):2677-83 [15735760.001]
  • [Cites] Mol Cell. 2005 Jul 1;19(1):123-33 [15989970.001]
  • [Cites] Cancer Res. 2004 Apr 15;64(8):2793-8 [15087395.001]
  • [Cites] Mol Cell Biol. 2006 Mar;26(5):1786-94 [16478998.001]
  • [Cites] Dev Biol. 2005 Dec 1;288(1):60-72 [16248995.001]
  • [Cites] Annu Rev Biochem. 2004;73:39-85 [15189136.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Mar 5;99(5):2872-7 [11867732.001]
  • [Cites] Nature. 2002 Sep 12;419(6903):135-41 [12226657.001]
  • [Cites] EMBO J. 2002 Mar 15;21(6):1456-64 [11889051.001]
  • [Cites] Dev Cell. 2005 Dec;9(6):769-79 [16326389.001]
  • [Cites] Cancer Cell. 2004 May;5(5):465-75 [15144954.001]
  • [Cites] Hum Mol Genet. 2005 May 15;14(10):1351-65 [15829507.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Apr 11;97(8):4046-51 [10759568.001]
  • [Cites] Mol Biol Cell. 2006 Apr;17 (4):1643-51 [16421255.001]
  • [Cites] Chembiochem. 2005 Oct;6(10 ):1735-43 [16142820.001]
  • [Cites] Cell. 2003 Nov 26;115(5):565-76 [14651848.001]
  • [Cites] J Biol Chem. 2005 Feb 11;280(6):4102-10 [15590687.001]
  • [Cites] Mol Cell. 2003 Apr;11(4):1043-54 [12718889.001]
  • [Cites] Exp Hematol. 2003 Jun;31(6):446-54 [12829019.001]
  • [Cites] Nature. 2005 Jul 21;436(7049):428-33 [15931174.001]
  • [Cites] J Biol Chem. 2004 Nov 26;279(48):50157-66 [15355988.001]
  • [Cites] J Biol Chem. 2002 Feb 15;277(7):4755-63 [11709548.001]
  • [Cites] Nucleic Acids Res. 2005 Jul 19;33(13):4023-34 [16030353.001]
  • [Cites] Nature. 2005 Jun 16;435(7044):979-82 [15959518.001]
  • [Cites] FEBS Lett. 1997 Jan 20;401(2-3):109-12 [9013868.001]
  • [Cites] Biochem Biophys Res Commun. 2001 Aug 17;286(2):322-7 [11500040.001]
  • [Cites] J Biol Chem. 2000 Jul 14;275(28):20963-6 [10806190.001]
  • [Cites] Genomics. 1996 Sep 1;36(2):271-9 [8812453.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Apr 2;93(7):2958-63 [8610150.001]
  • [Cites] EMBO J. 1999 Nov 15;18(22):6455-61 [10562557.001]
  • [Cites] Nucleic Acids Res. 2004 Jan 29;32(2):598-610 [14752048.001]
  • [Cites] Cell Cycle. 2002 Jul-Aug;1(4):245-9 [12429940.001]
  • [Cites] Mol Cell. 2004 Feb 27;13(4):611-7 [14992729.001]
  • (PMID = 16758298.001).
  • [ISSN] 1567-2379
  • [Journal-full-title] Journal of molecular histology
  • [ISO-abbreviation] J. Mol. Histol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / BC / BC 045418; United States / NCI NIH HHS / CA / CA 102630
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Chromatin; 0 / Enzymes; 0 / SUMO-1 Protein; 0 / Saccharomyces cerevisiae Proteins; EC 2.3.2.23 / RAD6 protein, S cerevisiae; EC 2.3.2.23 / Ubiquitin-Conjugating Enzymes; EC 2.7.7.- / Rad51 Recombinase; EC 3.6.4.- / DNA Helicases; EC 6.3.2.- / ubiquitin-conjugating enzyme UBC9
  •  go-up   go-down


77. Kajo K, Macháleková K: Collision of invasive serous adenocarcinoma and mature cystic teratoma in the ovary. Letter to the editor. APMIS; 2007 Jun;115(6):769-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Collision of invasive serous adenocarcinoma and mature cystic teratoma in the ovary. Letter to the editor.
  • [MeSH-major] Adenocarcinoma / complications. Ovarian Neoplasms / complications. Teratoma / complications

  • Genetic Alliance. consumer health - Teratoma.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] APMIS. 2005 Oct;113(10):713-5 [16309432.001]
  • (PMID = 17550386.001).
  • [ISSN] 0903-4641
  • [Journal-full-title] APMIS : acta pathologica, microbiologica, et immunologica Scandinavica
  • [ISO-abbreviation] APMIS
  • [Language] eng
  • [Publication-type] Case Reports; Comment; Letter
  • [Publication-country] Denmark
  •  go-up   go-down


78. Jin ZH, Josserand V, Razkin J, Garanger E, Boturyn D, Favrot MC, Dumy P, Coll JL: Noninvasive optical imaging of ovarian metastases using Cy5-labeled RAFT-c(-RGDfK-)4. Mol Imaging; 2006 Jul;5(3):188-97
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Noninvasive optical imaging of ovarian metastases using Cy5-labeled RAFT-c(-RGDfK-)4.
  • The aim of this study was to determine whether RAFT-c(-RGDfK-)4 combined with optical imaging could allow noninvasive detection of deep ovarian metastases.
  • Human ovarian adenocarcinoma IGROV1 cells expressing low levels of integrin alphaVbeta3 (the main receptor for the cRGD peptide) were used for in vitro and in vivo assays in combination with Cy5-labeled RAFT-c(-RGDfK-)4, cRGD, or RAFT-c(-RbetaADfK-)4.
  • [MeSH-major] Carbocyanines. Neoplasm Metastasis / radiography. Ovarian Neoplasms / radiography. Ovarian Neoplasms / secondary. Peptides, Cyclic

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16954034.001).
  • [ISSN] 1535-3508
  • [Journal-full-title] Molecular imaging
  • [ISO-abbreviation] Mol Imaging
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Carbocyanines; 0 / Carrier Proteins; 0 / Integrin alphaVbeta3; 0 / Peptides, Cyclic; 0 / Polymers; 0 / cyanine dye 5; 0 / cyclic arginine-glycine-aspartic acid peptide
  •  go-up   go-down


79. Karafin MS, Cummings CT, Fu B, Iacobuzio-Donahue CA: The developmental transcription factor Gata4 is overexpressed in pancreatic ductal adenocarcinoma. Int J Clin Exp Pathol; 2009 Aug 30;3(1):47-55
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The developmental transcription factor Gata4 is overexpressed in pancreatic ductal adenocarcinoma.
  • Silencing of GATA4 mRNA expression by promoter methylation has been implicated in carcinogenesis of the ovary, lung and colorectum.
  • By contrast, GATA4 mRNA expression is upregulated in pancreatic cancer cell lines and tissues.
  • To further clarify the relationship of GATA4 to pancreatic cancer, we immunolabeled 90 samples of pancreatic ductal adenocarcinoma using a GATA4 specific monoclonal antibody.
  • These findings support previous studies implicating GATA4 in pancreatic cancer and offer new avenues for investigation into this aggressive tumor type.

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Dev Biol. 2003 Mar 1;255(1):12-29 [12618131.001]
  • [Cites] Clin Cancer Res. 2009 Jun 15;15(12):3990-7 [19509152.001]
  • [Cites] Cancer Res. 2003 Aug 15;63(16):4967-77 [12941822.001]
  • [Cites] Nature. 2003 Oct 23;425(6960):846-51 [14520411.001]
  • [Cites] Nature. 2003 Oct 23;425(6960):851-6 [14520413.001]
  • [Cites] Mol Cell Biol. 2003 Dec;23(23):8429-39 [14612389.001]
  • [Cites] EMBO J. 1993 Dec 15;12(13):4993-5005 [8262042.001]
  • [Cites] Lab Invest. 1995 Apr;72(4):395-404 [7723277.001]
  • [Cites] Dev Biol. 1996 Jul 10;177(1):309-22 [8660897.001]
  • [Cites] Genes Dev. 1997 Apr 15;11(8):1048-60 [9136932.001]
  • [Cites] Genes Dev. 1998 Nov 15;12(22):3579-90 [9832509.001]
  • [Cites] Clin Cancer Res. 2004 Dec 1;10(23):7917-24 [15585625.001]
  • [Cites] Cancer Res. 2005 Mar 1;65(5):1619-26 [15753353.001]
  • [Cites] J Biol Chem. 2005 Jun 3;280(22):21022-8 [15793308.001]
  • [Cites] Development. 2005 Sep;132(17):4005-14 [16079152.001]
  • [Cites] Dev Dyn. 2005 Oct;234(2):355-62 [16127717.001]
  • [Cites] Dev Growth Differ. 2005 Dec;47(9):591-600 [16316404.001]
  • [Cites] Cancer Lett. 2006 Sep 28;241(2):281-8 [16337738.001]
  • [Cites] Oncogene. 2006 Aug 31;25(39):5446-61 [16607277.001]
  • [Cites] J Clin Endocrinol Metab. 2000 Oct;85(10):3925-31 [11061558.001]
  • [Cites] J Biol Chem. 2000 Dec 15;275(50):38949-52 [11042222.001]
  • [Cites] Genes Dev. 2002 Apr 1;16(7):784-9 [11937486.001]
  • [Cites] Curr Opin Genet Dev. 2002 Aug;12(4):416-22 [12100886.001]
  • [Cites] Int J Cancer. 2006 Nov 1;119(9):2078-83 [16823849.001]
  • [Cites] Dev Biol. 2006 Oct 15;298(2):415-29 [16887115.001]
  • [Cites] Cancer Res. 2007 Mar 1;67(5):2187-96 [17332349.001]
  • [Cites] Am J Respir Cell Mol Biol. 2007 Apr;36(4):391-7 [17142311.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 May 8;104(19):8053-8 [17463088.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Sep 18;104(38):14994-9 [17848526.001]
  • [Cites] Development. 2007 Dec;134(24):4459-68 [18003741.001]
  • [Cites] Cancer Biol Ther. 2007 Oct;6(10):1546-52 [17912029.001]
  • [Cites] BMC Mol Biol. 2008;9:44 [18445271.001]
  • [Cites] Development. 2008 Nov;135(22):3731-43 [18927154.001]
  • [Cites] Cancer Biol Ther. 2008 Oct;7(10):1593-601 [18769116.001]
  • [Cites] J Biol Chem. 1997 Mar 28;272(13):8515-24 [9079680.001]
  • [Cites] CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49 [19474385.001]
  • [Cites] J Mol Endocrinol. 2009 Oct;43(4):157-69 [19491195.001]
  • [Cites] Cancer Cell. 2003 Jun;3(6):565-76 [12842085.001]
  • (PMID = 19918328.001).
  • [ISSN] 1936-2625
  • [Journal-full-title] International journal of clinical and experimental pathology
  • [ISO-abbreviation] Int J Clin Exp Pathol
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / K08 CA106610; United States / NCI NIH HHS / CA / P50 CA062924; United States / NCI NIH HHS / CA / CA106610; United States / NCI NIH HHS / CA / CA62924
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / GATA4 Transcription Factor; 0 / GATA4 protein, human; 0 / RNA, Messenger
  • [Other-IDs] NLM/ PMC2776266
  • [Keywords] NOTNLM ; Pancreatic cancer / development / embryology / transcription factor
  •  go-up   go-down


80. Maruyama H, Ohyama N, Hosokawa Y, Momose H, Yamada K, Tsutsumi M, Kuniyasu H, Enomoto Y, Uematsu K, Konishi Y: Serous borderline tumor of the paratestis. Pathol Int; 2008 May;58(5):311-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Reported herein is a case of serous borderline tumor (SBT, ovarian epithelial type tumor) of the paratestis, involving the tunica vaginalis, in a 64-year-old man.
  • The patient complained of right hydrocele; puncture cytology of the turbid fluid pointed to an adenocarcinoma.
  • On microscopy small papillary epithelial lesions were found with psammoma bodies and intraglandular papillary lesions were irregularly recognized in the stroma of the paratestis, similar to SBT of the ovary.
  • Ultrastructurally, the cells did not demonstrate any well-developed microvilli or secretory granules and immunohistochemical findings supported SBT of Müllerian type (ovarian epithelial type tumor), while excluding a papillary type of malignant mesothelioma.
  • The lesion in the present case was concluded to be a testicular serous tumor of Müllerian type, similar to SBT of the ovary.

  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18429831.001).
  • [ISSN] 1440-1827
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


81. Matsuura Y, Kitajima M, Hachisuga T, Tanimoto A, Okura N, Kihara I: Malignant mixed müllerian tumor with malignant neuroectodermal components (teratoid carcinosarcoma) of the ovary: Report of a case with clinicopathologic findings. J Obstet Gynaecol Res; 2010 Aug;36(4):907-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant mixed müllerian tumor with malignant neuroectodermal components (teratoid carcinosarcoma) of the ovary: Report of a case with clinicopathologic findings.
  • Malignant ovarian tumor composed of müllerian epithelial tumor and malignant germ cell tumor is also rare, with most cases composed of endometrioid adenocarcinoma and yolk sac tumor.
  • Ovarian MMMT with malignant neuroectodermal components resembling immature teratoma is extremely rare.
  • We report a case of teratoid carcinosarcoma of the ovary occurring in a 40-year-old female.
  • This quite rare ovarian tumor closely resembled nasopharyngeal tumors described as 'teratoid carcinosarcoma' is biologically aggressive.
  • We report the fourth case of ovarian teratoid carcinosarcoma.
  • Further cases need to be accumulated to make diagnosis and to determine a successful treatment modality.
  • [MeSH-major] Carcinosarcoma / pathology. Mixed Tumor, Mullerian / pathology. Ovarian Neoplasms / pathology. Teratoma / pathology
  • [MeSH-minor] Adult. Fatal Outcome. Female. Humans. Ovary / pathology. Ovary / surgery

  • Genetic Alliance. consumer health - Malignant mixed Mullerian tumor.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20666968.001).
  • [ISSN] 1447-0756
  • [Journal-full-title] The journal of obstetrics and gynaecology research
  • [ISO-abbreviation] J. Obstet. Gynaecol. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


82. Zhang W, Shannon WD, Duncan J, Scheffer GL, Scheper RJ, McLeod HL: Expression of drug pathway proteins is independent of tumour type. J Pathol; 2006 Jun;209(2):213-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Many enzymes are involved in controlling the disposition of irinotecan, including the cellular target (TOP1), metabolism enzymes (CES2, UGT1A1, CYP3A4, CYP3A5), and cellular transporters of the anti-cancer agent (ABCB1, ABCC1, ABCC2, ABCC3, ABCC5, ABCG2).
  • These 11 proteins were evaluated in tissue microarrays containing colon, breast, prostate, ovary, and lung cancers; brain tumours; melanoma; lymphoma; and selected normal tissues.
  • The anatomy independence of drug pathways stimulates efforts to move away from our traditional approaches to the selection of cancer therapy.
  • [MeSH-minor] Adenocarcinoma / chemistry. Adenocarcinoma / enzymology. Brain Neoplasms / chemistry. Brain Neoplasms / enzymology. Breast Neoplasms / chemistry. Breast Neoplasms / enzymology. Colonic Neoplasms / chemistry. Colonic Neoplasms / enzymology. Cytochrome P-450 Enzyme System / analysis. Drug Resistance, Neoplasm. Enzyme Inhibitors / analysis. Female. Humans. Immunohistochemistry / methods. Lung Neoplasms / chemistry. Lung Neoplasms / enzymology. Lymphoma / chemistry. Lymphoma / enzymology. Male. Melanoma / chemistry. Melanoma / enzymology. Multidrug Resistance-Associated Proteins / analysis. Ovarian Neoplasms / chemistry. Ovarian Neoplasms / enzymology. Prostatic Neoplasms / chemistry. Prostatic Neoplasms / enzymology. Tissue Array Analysis / methods

  • COS Scholar Universe. author profiles.
  • Pharmacogenomics Knowledge Base. meta-databases - Pharmacogenomic Annotation 827851551 for PMID:16508919 [PharmGKB] .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16508919.001).
  • [ISSN] 0022-3417
  • [Journal-full-title] The Journal of pathology
  • [ISO-abbreviation] J. Pathol.
  • [Language] eng
  • [Grant] United States / NIGMS NIH HHS / GM / GM61218; United States / NIGMS NIH HHS / GM / GM63340; United States / NCI NIH HHS / CA / P30 CA091842
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Enzyme Inhibitors; 0 / Multidrug Resistance-Associated Proteins; 0 / Neoplasm Proteins; 7673326042 / irinotecan; 9035-51-2 / Cytochrome P-450 Enzyme System; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


83. Marwah N, Bansal C, Gupta S, Singh S, Sapna, Arora B: Immunohistochemical study of the expression of HER-2/neu oncogene in ovarian lesions. Indian J Pathol Microbiol; 2007 Jul;50(3):489-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical study of the expression of HER-2/neu oncogene in ovarian lesions.
  • To evaluate the expression of HER-2/neu in various ovarian lesions, 75 cases of ovarian tissues (25 cases of benign lesions and 50 cases of carcinoma) were studied in the department of pathology, Pt. B.D.
  • It was observed that HER-2/neu expression was significantly associated with high grade ovarian tumours, however intensity of positivity did not correlate with the grade of tumour.
  • [MeSH-major] Adenocarcinoma / metabolism. Carcinoma / metabolism. Ovarian Neoplasms / metabolism. Ovary / metabolism. Receptor, ErbB-2 / metabolism

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17883115.001).
  • [ISSN] 0377-4929
  • [Journal-full-title] Indian journal of pathology & microbiology
  • [ISO-abbreviation] Indian J Pathol Microbiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


84. Nourbakhsh M, Golestani A, Zahrai M, Modarressi MH, Malekpour Z, Karami-Tehrani F: Androgens stimulate telomerase expression, activity and phosphorylation in ovarian adenocarcinoma cells. Mol Cell Endocrinol; 2010 Dec 15;330(1-2):10-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Androgens stimulate telomerase expression, activity and phosphorylation in ovarian adenocarcinoma cells.
  • Androgens have been implicated in increasing ovarian cancer risk.
  • Most ovarian cancer cells have high telomerase activity which is effective in inducing ovarian carcinogenesis.
  • The purpose of this study was to investigate the effects of testosterone and androstenedione on the viability of an ovarian adenocarcinoma cell line, the activity and expression of telomerase, and the phosphorylation status of its catalytic subunit in these cells.
  • Results showed that androgens significantly increased the viability of ovarian cancer cells and that these hormones induced the expression, activity and phosphorylation of telomerase.
  • These findings might have implications for understanding the role of androgens in ovarian carcinogenesis.
  • [MeSH-major] Adenocarcinoma / enzymology. Androgens / pharmacology. Gene Expression Regulation, Neoplastic / drug effects. Ovarian Neoplasms / enzymology. Telomerase / metabolism

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. TESTOSTERONE .
  • Hazardous Substances Data Bank. ANDROSTENEDIONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Ireland Ltd. All rights reserved.
  • (PMID = 20673788.001).
  • [ISSN] 1872-8057
  • [Journal-full-title] Molecular and cellular endocrinology
  • [ISO-abbreviation] Mol. Cell. Endocrinol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Androgens; 0 / Protein Kinase Inhibitors; 0 / RNA, Messenger; 3XMK78S47O / Testosterone; 409J2J96VR / Androstenedione; EC 2.7.1.137 / Phosphatidylinositol 3-Kinase; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt; EC 2.7.7.49 / TERT protein, human; EC 2.7.7.49 / Telomerase
  •  go-up   go-down


85. Wang KL, Yang YC, Lai JC, Tsai TH, Lin CP, Wu YT, Chen YY, Wang SC, Chen YJ: Comparison in purity and antitumor effect of brand and generic paclitaxel against human ovarian cancer cells by an in vitro experimental model. Drug Dev Ind Pharm; 2010 Oct;36(10):1253-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison in purity and antitumor effect of brand and generic paclitaxel against human ovarian cancer cells by an in vitro experimental model.
  • By assessing the IC(50), generic paclitaxel also exhibited a greater inhibitory activity on clonogenicity of human ovarian adenocarcinoma SKOV-3 cells.
  • DISCUSSION AND CONCLUSION: The results suggest that generic paclitaxel may possess a greater cell death inducing capacity and clonogenicity inhibitory activity against ovarian cancer cells than the original brand Taxol of the same purity.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / chemistry. Antineoplastic Agents, Phytogenic / therapeutic use. Drugs, Generic / chemistry. Drugs, Generic / therapeutic use. Ovarian Neoplasms / drug therapy. Paclitaxel / chemistry. Paclitaxel / therapeutic use
  • [MeSH-minor] Adenocarcinoma, Clear Cell / drug therapy. Apoptosis / drug effects. Cell Cycle / drug effects. Cell Line, Tumor. Cell Survival. Drug Screening Assays, Antitumor. Female. Humans. Mitosis / drug effects

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20818963.001).
  • [ISSN] 1520-5762
  • [Journal-full-title] Drug development and industrial pharmacy
  • [ISO-abbreviation] Drug Dev Ind Pharm
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Drugs, Generic; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


86. Sciallis AP, Aubry MC, Bell DA: Ciliated adenocarcinoma of the ovary with evidence of serous differentiation: report of a case. Int J Gynecol Pathol; 2009 Sep;28(5):447-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ciliated adenocarcinoma of the ovary with evidence of serous differentiation: report of a case.
  • A patient with bilateral ovarian adenocarcinomas composed predominantly of ciliated cells incidentally found at autopsy is reported.
  • The tumor was confined to the ovaries without evidence of metastatic spread.
  • [MeSH-major] Adenocarcinoma / pathology. Cilia / pathology. Ovarian Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19696614.001).
  • [ISSN] 1538-7151
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


87. Ang D, Ng KY, Tan HK, Chung AY, Yew BS, Lee VK: Ovarian carcinoma presenting with isolated contralateral inguinal lymph node metastasis: a case report. Ann Acad Med Singapore; 2007 Jun;36(6):427-30
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ovarian carcinoma presenting with isolated contralateral inguinal lymph node metastasis: a case report.
  • INTRODUCTION: Ovarian carcinoma usually presents at an advanced stage with diffuse intraabdominal manifestations.
  • CLINICAL PICTURE: The only clinical abnormality was an enlarged right inguinal lymph node (3 x 2 cm), for which excision biopsy revealed metastatic adenocarcinoma.
  • A computed tomography (CT) scan showed an enlarged left ovarian lesion (9.0 x 6.4 cm).
  • Histology confirmed left ovarian adenocarcinoma, consistent with the earlier histology of the right inguinal lymph node.
  • Postoperatively, the patient received adjuvant chemotherapy for treatment of FIGO Stage IIIc ovarian carcinoma and is clinically disease free 13 months after surgery.
  • CONCLUSIONS: Ovarian cancer presenting with inguinal lymph node metastases is uncommon.
  • Ovarian cancer which manifests solely as a contralateral inguinal lymph node metastasis has not been previously reported.
  • This case illustrates a rare presentation of ovarian carcinoma, and underscores the need to consider ovarian carcinoma in the differential diagnosis of women with inguinal lymphadenopathy.
  • [MeSH-major] Adenocarcinoma / pathology. Ovarian Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17597969.001).
  • [ISSN] 0304-4602
  • [Journal-full-title] Annals of the Academy of Medicine, Singapore
  • [ISO-abbreviation] Ann. Acad. Med. Singap.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Singapore
  •  go-up   go-down


88. Yadav S, van Vlerken LE, Little SR, Amiji MM: Evaluations of combination MDR-1 gene silencing and paclitaxel administration in biodegradable polymeric nanoparticle formulations to overcome multidrug resistance in cancer cells. Cancer Chemother Pharmacol; 2009 Mar;63(4):711-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluations of combination MDR-1 gene silencing and paclitaxel administration in biodegradable polymeric nanoparticle formulations to overcome multidrug resistance in cancer cells.
  • Upon administration in multidrug resistant SKOV3(TR) human ovarian adenocarcinoma cells, siRNA-mediated MDR-1 gene silencing was evident at 100 nM dose.
  • [MeSH-major] Drug Resistance, Multiple. Gene Silencing. Nanoparticles. Ovarian Neoplasms / therapy. P-Glycoprotein / genetics. Paclitaxel / administration & dosage. Polyesters / administration & dosage

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. TAXOL .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18618115.001).
  • [ISSN] 1432-0843
  • [Journal-full-title] Cancer chemotherapy and pharmacology
  • [ISO-abbreviation] Cancer Chemother. Pharmacol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01-CA119617
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / ABCB1 protein, human; 0 / Antineoplastic Agents, Phytogenic; 0 / P-Glycoprotein; 0 / P-Glycoproteins; 0 / Polyesters; 0 / RNA, Small Interfering; 0 / polyethylene oxide-polycaprolactone copolymer; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


89. Lee SJ, Bae JH, Lee AW, Tong SY, Park YG, Park JS: Clinical characteristics of metastatic tumors to the ovaries. J Korean Med Sci; 2009 Feb;24(1):114-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical characteristics of metastatic tumors to the ovaries.
  • Approximately 5-30% of the ovarian cancers are metastatic malignancies.
  • The prevalence of metastatic ovarian tumors varies with the incidence rates and spread patterns of primary malignancies.
  • We evaluated the prevalence, pre- and postoperative characteristics of metastatic ovarian cancer in Korean women.
  • We reviewed the records for 821 ovarian malignancies with pathological consultation from 1996-2006 and recorded patient demographical, radiological, histopathological, and survival data.
  • The study included 112 cases of histologically confirmed metastatic ovarian cancer.
  • Metastatic ovarian cancer accounted for 13.6% of all ovarian malignancy, primarily arising from the gastrointestinal tract.
  • The preoperative detection rate with imaging was 75%, and none of the radiological or serological features were useful for differential diagnosis.
  • The differential diagnosis of metastatic ovarian cancer can be problematic, so multiple diagnostic approaches are necessary.
  • [MeSH-major] Adenocarcinoma / diagnosis. Adenocarcinoma / secondary. Ovarian Neoplasms / diagnosis. Ovarian Neoplasms / secondary
  • [MeSH-minor] Adult. CA-125 Antigen / blood. Data Interpretation, Statistical. Diagnosis, Differential. Female. Gastrointestinal Neoplasms / diagnosis. Gastrointestinal Neoplasms / pathology. Humans. Medical Records. Middle Aged. Ovariectomy. Prognosis. Retrospective Studies. Risk Factors. Survival Analysis

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Radiology. 2001 Apr;219(1):213-8 [11274559.001]
  • [Cites] Abdom Imaging. 2007 Nov;32(6):784-95 [17318680.001]
  • [Cites] Oncology. 2002;63(2):124-9 [12239446.001]
  • [Cites] J Ultrasound Med. 2003 Mar;22(3):243-7 [12636323.001]
  • [Cites] Gynecol Oncol. 2003 May;89(2):314-7 [12713997.001]
  • [Cites] Gynecol Oncol. 2003 Aug;90(2):397-401 [12893207.001]
  • [Cites] Gynecol Oncol. 2004 Apr;93(1):87-91 [15047218.001]
  • [Cites] Gynecol Oncol. 2004 Aug;94(2):477-82 [15297191.001]
  • [Cites] J Comput Assist Tomogr. 2005 Jan-Feb;29(1):69-73 [15665686.001]
  • [Cites] Mod Pathol. 2005 Feb;18 Suppl 2:S99-111 [15492758.001]
  • [Cites] Clin Cancer Res. 2005 May 15;11(10):3766-72 [15897574.001]
  • [Cites] Gynecol Oncol. 2005 Aug;98(2):235-41 [15982725.001]
  • [Cites] Histopathology. 2005 Sep;47(3):231-47 [16115224.001]
  • [Cites] Gynecol Oncol. 2006 Apr;101(1):97-101 [16278010.001]
  • [Cites] Int J Gynecol Cancer. 2006 Jan-Feb;16 Suppl 1:132-8 [16515581.001]
  • [Cites] J Natl Cancer Inst. 2006 Apr 19;98(8):511 [16622117.001]
  • [Cites] Anticancer Res. 2006 May-Jun;26(3B):2339-44 [16821613.001]
  • [Cites] Gynecol Oncol. 2007 Jul;106(1):193-200 [17466362.001]
  • [Cites] Eur J Obstet Gynecol Reprod Biol. 2008 Jan;136(1):78-82 [17049712.001]
  • [Cites] Gynecol Oncol. 2001 Jul;82(1):105-9 [11426970.001]
  • (PMID = 19270823.001).
  • [ISSN] 1598-6357
  • [Journal-full-title] Journal of Korean medical science
  • [ISO-abbreviation] J. Korean Med. Sci.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 0 / CA-125 Antigen
  • [Other-IDs] NLM/ PMC2650975
  • [Keywords] NOTNLM ; Diagnostic Imaging / Metastasis / Ovary / Prevalence / Surgical Procedures
  •  go-up   go-down


90. Su Y, Zheng L, Wang Q, Bao J, Cai Z, Liu A: The PI3K/Akt pathway upregulates Id1 and integrin α4 to enhance recruitment of human ovarian cancer endothelial progenitor cells. BMC Cancer; 2010;10:459
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The PI3K/Akt pathway upregulates Id1 and integrin α4 to enhance recruitment of human ovarian cancer endothelial progenitor cells.
  • We aimed to determine whether inhibitors of differentiation 1 (Id1) were expressed in circulating EPCs of patients with ovarian cancer, whether Id1 could mediate EPCs mobilization and recruitment, and, if so, what underlying signaling pathway it used.
  • METHODS: Circulating EPCs cultures were from 25 patients with ovarian cancer and 20 healthy control subjects.
  • RESULTS: Id1 and integrin α4 expression were increased in EPCs freshly isolated from ovarian cancer patients compared to those obtained from healthy subjects. siRNA-mediated Id1 downregulation substantially reduced EPCs function and integrin α4 expression.
  • [MeSH-major] Endothelial Cells / metabolism. Inhibitor of Differentiation Protein 1 / metabolism. Integrin alpha4 / metabolism. Ovarian Neoplasms / metabolism. Ovarian Neoplasms / pathology. Phosphatidylinositol 3-Kinases / metabolism. Proto-Oncogene Proteins c-akt / metabolism. Stem Cells / metabolism
  • [MeSH-minor] Adenocarcinoma, Mucinous / genetics. Adenocarcinoma, Mucinous / metabolism. Adenocarcinoma, Mucinous / pathology. Adolescent. Adult. Blotting, Western. Case-Control Studies. Cell Adhesion. Cell Movement. Cell Proliferation. Cystadenocarcinoma, Serous / genetics. Cystadenocarcinoma, Serous / metabolism. Cystadenocarcinoma, Serous / pathology. Endometrial Neoplasms / genetics. Endometrial Neoplasms / metabolism. Endometrial Neoplasms / pathology. Female. Humans. Middle Aged. Ovary / metabolism. Ovary / pathology. Prognosis. RNA, Messenger / genetics. RNA, Small Interfering / pharmacology. Reverse Transcriptase Polymerase Chain Reaction. Signal Transduction. Up-Regulation. Young Adult

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • MedlinePlus Health Information. consumer health - Stem Cells.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Oncol. 2003 Jul;14(7):1086-93 [12853351.001]
  • [Cites] Nat Med. 2001 Nov;7(11):1194-201 [11689883.001]
  • [Cites] Br J Cancer. 2004 Dec 13;91(12):2042-7 [15599381.001]
  • [Cites] J Clin Invest. 2006 Mar;116(3):652-62 [16498499.001]
  • [Cites] FASEB J. 2006 Jul;20(9):1495-7 [16754748.001]
  • [Cites] Nature. 1999 Oct 14;401(6754):670-7 [10537105.001]
  • [Cites] BMC Cancer. 2009;9:430 [20003244.001]
  • [Cites] Oncogene. 2001 Dec 20;20(58):8334-41 [11840326.001]
  • [Cites] Cancer Res. 2006 Jul 15;66(14):7341-7 [16849585.001]
  • [Cites] Blood. 2006 Aug 1;108(3):915-21 [16861344.001]
  • [Cites] Science. 2006 Sep 22;313(5794):1785-7 [16990548.001]
  • [Cites] Nat Rev Cancer. 2006 Nov;6(11):835-45 [17036040.001]
  • [Cites] Cancer Res. 2006 Nov 15;66(22):10870-7 [17108123.001]
  • [Cites] Prog Cardiovasc Dis. 2007 May-Jun;49(6):421-9 [17498522.001]
  • [Cites] PLoS One. 2007;2(12):e1338 [18092003.001]
  • [Cites] Science. 2008 Jan 11;319(5860):195-8 [18187653.001]
  • [Cites] Nat Clin Pract Oncol. 2008 Apr;5(4):194-204 [18268546.001]
  • [Cites] J Biol Chem. 2008 Aug 15;283(33):22410-6 [18556654.001]
  • [Cites] Regen Med. 2008 Nov;3(6):863-76 [18947309.001]
  • [Cites] In Vivo. 2008 Nov-Dec;22(6):831-6 [19181016.001]
  • [Cites] Adv Cancer Res. 2004;92:81-94 [15530557.001]
  • (PMID = 20796276.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / ID1 protein, human; 0 / Inhibitor of Differentiation Protein 1; 0 / RNA, Messenger; 0 / RNA, Small Interfering; 143198-26-9 / Integrin alpha4; EC 2.7.1.- / Phosphatidylinositol 3-Kinases; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt
  • [Other-IDs] NLM/ PMC2940800
  •  go-up   go-down


91. Yoshioka N, Suzuki N, Uekawa A, Kiguchi K, Ishizuka B: POU6F1 is the transcription factor that might be involved in cell proliferation of clear cell adenocarcinoma of the ovary. Hum Cell; 2009 Nov;22(4):94-100
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] POU6F1 is the transcription factor that might be involved in cell proliferation of clear cell adenocarcinoma of the ovary.
  • Clear cell adenocarcinoma of the ovary often shows resistance to anticancer agents.
  • We investigated new molecules to use when developing molecular-targeting therapy for clear cell adenocarcinoma of the ovary.
  • RMG-I cells without invasive potential and RMG-V cells with invasive potential (derived from clear cell adenocarcinoma of the ovary) were subjected to complementary deoxyribonucleic acid microarray analysis.
  • The results showed suppression of RMG-V cell infiltration by siRNA, but proliferation of the cancer cells was also suppressed.
  • These findings suggested that POU6F1 might be a transcription factor involved in the proliferation of ovarian cancer cells.
  • Clear cell adenocarcinoma of the ovary shows little response to standard therapy.
  • The results of the present study suggest that the transcription factor POU6F1 could be a new molecular target for treatment of this cancer.
  • [MeSH-major] Adenocarcinoma, Clear Cell / pathology. Cell Proliferation. Ovarian Neoplasms / pathology. POU Domain Factors / physiology. Transcription Factors / physiology

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hum Cell. 2005 Sep;18(3):147-55 [17022147.001]
  • [Cites] Biochem Biophys Res Commun. 1996 Mar 18;220(2):274-9 [8645295.001]
  • [Cites] J Biol Chem. 1993 Apr 5;268(10):7449-57 [8463278.001]
  • [Cites] Cancer Lett. 2008 Sep 18;268(2):187-201 [18482795.001]
  • [Cites] Oncogene. 2007 Oct 18;26(48):6851-62 [17471232.001]
  • [Cites] Exp Cell Res. 2007 Apr 15;313(7):1307-17 [17359972.001]
  • [Cites] Am J Pathol. 2005 Nov;167(5):1411-27 [16251425.001]
  • [Cites] Surg Gynecol Obstet. 1989 Sep;169(3):226-32 [2772792.001]
  • [Cites] Int J Clin Oncol. 2007 Aug;12 (4):256-60 [17701003.001]
  • [Cites] Int J Gynecol Pathol. 2000 Jan;19(1):7-15 [10638449.001]
  • (PMID = 19874398.001).
  • [ISSN] 1749-0774
  • [Journal-full-title] Human cell
  • [ISO-abbreviation] Hum. Cell
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Caveolin 1; 0 / POU Domain Factors; 0 / POU6F1 protein, human; 0 / Transcription Factors
  •  go-up   go-down


92. Shah VB, Amonkar GP, Deshpande JR, Bhalekar H: Mucinous adenocarcinoma of the renal pelvis with pseudomyxoma peritonei. Indian J Pathol Microbiol; 2008 Oct-Dec;51(4):536-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mucinous adenocarcinoma of the renal pelvis with pseudomyxoma peritonei.
  • Mucinous adenocarcinoma of the renal pelvis is an extremely rare tumor with very few case reports in literature.
  • It occurs secondary to primary mucinous neoplasms of particularly the appendix and the ovary.
  • Thus, a diagnosis of mucinous adenocarcinoma of the renal pelvis leading to pseudomyxoma peritonei was made.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Kidney Neoplasms / pathology. Kidney Pelvis / pathology. Neoplasms, Multiple Primary / pathology. Peritoneal Neoplasms / pathology. Pseudomyxoma Peritonei / pathology

  • Genetic Alliance. consumer health - Pseudomyxoma peritonei.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19008588.001).
  • [ISSN] 0377-4929
  • [Journal-full-title] Indian journal of pathology & microbiology
  • [ISO-abbreviation] Indian J Pathol Microbiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  •  go-up   go-down


93. Chênevert J, Bessette P, Plante M, Têtu B, Dubé V: Mixed ovarian large cell neuroendocrine carcinoma, mucinous adenocarcinoma, and teratoma: a report of two cases and review of the literature. Pathol Res Pract; 2009;205(9):657-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mixed ovarian large cell neuroendocrine carcinoma, mucinous adenocarcinoma, and teratoma: a report of two cases and review of the literature.
  • Large cell neuroendocrine carcinoma of the ovary is a rare recently established entity.
  • Histological assessment revealed large cell neuroendocrine carcinoma admixed with mucinous adenocarcinoma and teratoma.
  • Different hypotheses regarding the origin of large cell neuroendocrine carcinoma of the ovary are discussed.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Carcinoma, Neuroendocrine / pathology. Neoplasms, Multiple Primary / pathology. Ovarian Neoplasms / pathology. Teratoma / pathology

  • Genetic Alliance. consumer health - Teratoma.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19577382.001).
  • [ISSN] 1618-0631
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


94. Guerrero MA, Kebebew E: Adrenocortical carcinoma and synchronous malignancies. J Cancer; 2010;1:108-11
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: In this report we describe a 32-year-old woman who on work-up for abnormal vaginal bleeding was diagnosed with synchronous uterine adenocarcinoma, ovarian adenocarcinoma and ACC.
  • RESULTS AND CONCLUSIONS: To our knowledge this is the first report of a patient with synchronous malignant tumors of the uterus, ovary and adrenal gland.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20842232.001).
  • [ISSN] 1837-9664
  • [Journal-full-title] Journal of Cancer
  • [ISO-abbreviation] J Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  • [Other-IDs] NLM/ PMC2938073
  • [Keywords] NOTNLM ; Adrenocortical carcinoma / Ovarian cancer / Synchronous malignancies / Uterine cancer / and Hereditary syndrome
  •  go-up   go-down


95. Kato N, Sasou S, Teshima S, Motoyama T: Overexpression of laminin-5 gamma2 chain in clear cell carcinoma of the ovary. Virchows Arch; 2007 Mar;450(3):273-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Overexpression of laminin-5 gamma2 chain in clear cell carcinoma of the ovary.
  • One of the characteristic microscopic features of ovarian clear cell carcinoma (CCC) is the densely hyaline basement membrane material expanding the stroma.
  • [MeSH-major] Adenocarcinoma, Clear Cell / metabolism. Laminin / metabolism. Ovarian Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Cell Biol. 1991 Aug;114(3):567-76 [1860885.001]
  • [Cites] Exp Cell Res. 2004 Jul 15;297(2):508-20 [15212952.001]
  • [Cites] Cancer Res. 1999 Nov 1;59(21):5596-601 [10554040.001]
  • [Cites] Cancer Res. 1995 Sep 15;55(18):4132-9 [7664291.001]
  • [Cites] Hum Pathol. 2005 May;36(5):522-30 [15948119.001]
  • [Cites] J Cell Biol. 1984 Apr;98(4):1474-80 [6715409.001]
  • [Cites] J Biol Chem. 2000 Oct 13;275(41):31896-907 [10926936.001]
  • [Cites] J Cell Biochem. 2004 Jul 1;92(4):701-14 [15211568.001]
  • [Cites] Int J Gynaecol Obstet. 2000 Aug;70(2):209-62 [11041682.001]
  • [Cites] Cell. 1991 May 17;65(4):599-610 [2032285.001]
  • [Cites] Science. 1997 Jul 11;277(5323):225-8 [9211848.001]
  • [Cites] J Cell Biochem. 2003 Feb 15;88(3):506-20 [12532327.001]
  • [Cites] Cancer. 1999 Jun 1;85(11):2315-21 [10357399.001]
  • [Cites] Cancer Sci. 2006 Feb;97(2):91-8 [16441418.001]
  • [Cites] J Cell Biol. 2000 Feb 7;148(3):615-24 [10662785.001]
  • [Cites] J Histochem Cytochem. 2005 Oct;53(10):1293-300 [15923364.001]
  • [Cites] Int J Cancer. 1998 Mar 30;76(1):63-72 [9533763.001]
  • [Cites] Int J Gynecol Pathol. 1999 Jan;18(1):52-7 [9891241.001]
  • [Cites] Gynecol Oncol. 1990 Jul;38(1):37-45 [2354825.001]
  • [Cites] J Pathol. 1996 Nov;180(3):290-4 [8958807.001]
  • (PMID = 17235566.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antibodies, Blocking; 0 / Biomarkers, Tumor; 0 / Integrin alpha3; 0 / LAMC2 protein, human; 0 / Laminin
  •  go-up   go-down


96. Samaila MO, Adesiyun AG, Oluwole OP: Metastatic ovarian squamous cell carcinoma. Singapore Med J; 2008 May;49(5):e139-41
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic ovarian squamous cell carcinoma.
  • Ovarian squamous cell carcinoma is usually associated with germ cell tumours (dermoid cyst) or endometriosis in primary cancer.
  • While tumour metastasis to the ovary is common and often bilateral in over 50 percent of cases, metastatic cervical squamous cell carcinoma to the ovary is infrequent compared to adenocarcinoma from other extraovarian primaries and the cervix.
  • We report two cases of unilateral metastatic ovarian squamous cell carcinoma from the uterine cervix in two women aged 38 years and 48 years, respectively.
  • They presented with abdominopelvic masses, clinically thought to be tuberculosis and primary ovarian tumour, respectively.
  • Both had laparotomy which revealed multinodular ovarian masses with extensive extra-ovarian involvement of the corpus and uterine cervix by tumour and omental seedlings.
  • Tissue microscopy showed total replacement of ovarian stroma by tumour with necrotic foci and containing infiltrating nests and cords of malignant squamous cells with prominent intercellular bridges.
  • They were both diagnosed with metastatic ovarian squamous cell carcinoma with advanced stage disease primary in the uterine cervix.
  • Ovarian metastatic squamous cell carcinoma from the uterine cervix may occur with advanced stage cervical carcinoma.
  • Unilateral multinodular ovarian mass with extensive extra-ovarian tumour involvement should raise suspicion of metastasis rather than of primary tumour.
  • Early and prompt diagnosis is desirable in the management of these patients.
  • [MeSH-major] Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / secondary. Ovarian Neoplasms / secondary. Uterine Cervical Neoplasms / pathology


97. Ganta S, Devalapally H, Amiji M: Curcumin enhances oral bioavailability and anti-tumor therapeutic efficacy of paclitaxel upon administration in nanoemulsion formulation. J Pharm Sci; 2010 Nov;99(11):4630-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The results of this study suggest that combination of PTX and CUR, administered in nanoemulsions, could improve oral bioavailability and therapeutic efficacy in ovarian adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Agents, Phytogenic / pharmacokinetics. Antineoplastic Agents, Phytogenic / therapeutic use. Curcumin / pharmacology. Enzyme Inhibitors / pharmacology. Ovarian Neoplasms / drug therapy. Paclitaxel / pharmacokinetics. Paclitaxel / therapeutic use

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. CURCUMIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 Wiley-Liss, Inc. and the American Pharmacists Association
  • (PMID = 20845461.001).
  • [ISSN] 1520-6017
  • [Journal-full-title] Journal of pharmaceutical sciences
  • [ISO-abbreviation] J Pharm Sci
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01-CA119617
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Emulsions; 0 / Enzyme Inhibitors; 0 / P-Glycoprotein; EC 1.14.14.1 / Cytochrome P-450 CYP3A; IT942ZTH98 / Curcumin; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


98. Wamunyokoli FW, Bonome T, Lee JY, Feltmate CM, Welch WR, Radonovich M, Pise-Masison C, Brady J, Hao K, Berkowitz RS, Mok S, Birrer MJ: Expression profiling of mucinous tumors of the ovary identifies genes of clinicopathologic importance. Clin Cancer Res; 2006 Feb 1;12(3 Pt 1):690-700
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression profiling of mucinous tumors of the ovary identifies genes of clinicopathologic importance.
  • PURPOSE: To elucidate the molecular mechanisms contributing to the unique clinicopathologic characteristics of mucinous ovarian carcinoma, global gene expression profiling of mucinous ovarian tumors was carried out.
  • Hierarchical clustering and binary tree prediction analysis were used to determine the relationships among mucinous specimens and a series of previously profiled microdissected serous tumors and normal ovarian surface epithelium.
  • RESULTS: Comparison of the gene profiles between mucinous tumors and normal ovarian epithelial cells identified 1,599, 2,916, and 1,765 differentially expressed in genes in the cystadenomas, LMP tumors, and adenocarcinomas, respectively.
  • Furthermore, the cystadenomas coexpressed a subset of genes that were differentially regulated in LMP and adenocarcinoma specimens compared with normal ovarian surface epithelium.
  • PathwayAssist highlighted pathways with expression of genes involved in drug resistance in both LMP and adenocarcinoma samples.
  • CONCLUSIONS: These data provide a useful basis for understanding the molecular events leading to the development and progression of mucinous ovarian cancer.
  • [MeSH-major] Adenocarcinoma, Mucinous / genetics. Adenocarcinoma, Mucinous / pathology. Gene Expression Profiling. Gene Expression Regulation, Neoplastic. Ovarian Neoplasms / genetics. Ovarian Neoplasms / pathology
  • [MeSH-minor] Cluster Analysis. Decision Trees. Diagnosis, Differential. Female. Humans. Oligonucleotide Array Sequence Analysis / methods. Predictive Value of Tests

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16467078.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P50CA165009; United States / NCI NIH HHS / CA / R33CA103595; United States / Intramural NIH HHS / /
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  •  go-up   go-down


99. Ota K, Ito K, Akahira J, Sato N, Onogawa T, Moriya T, Unno M, Abe T, Niikura H, Takano T, Yaegashi N: Expression of organic cation transporter SLC22A16 in human epithelial ovarian cancer: a possible role of the adriamycin importer. Int J Gynecol Pathol; 2007 Jul;26(3):334-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of organic cation transporter SLC22A16 in human epithelial ovarian cancer: a possible role of the adriamycin importer.
  • Adriamycin is considered to be an active agent for ovarian cancer.
  • Recently, the benefit of adding adriamycin to the current standard regimen, paclitaxel and platinum, is evaluated to improve the outcome of patients with ovarian cancer.
  • Therefore, we examined the expression of SLC22A16 in ovarian cancers.
  • Twelve ovarian carcinoma cell lines were used for immunoblotting and reverse transcription-polymerase chain reaction to confirm the expression of SLC22A16 mRNA and protein.
  • Five normal ovaries, 12 ovarian adenomas, and 94 ovarian cancer cases were obtained from patients after surgical therapy.
  • The median value of relative SLC22A16 gene expression in cell lines derived from clear-cell adenocarcinoma was significantly higher than that in cell lines from other histologies (P < 0.001).
  • Expression of SLC22A16 protein was also detected in cell lines derived from clear-cell adenocarcinoma.
  • The SLC22A16 immunoreactivity was detected in 15 (16%) of 94 epithelial ovarian cancer, 1 (8.3%) of 12 benign adenomas, but 0 (0%) of 5 normal ovary cases.
  • In ovarian cancer tissues, SLC22A16 immunoreactivity was detected in 2 (5%) of 38 serous adenocarcinoma, 1 (6.7%) of 15 endometrioid adenocarcinoma, 0 (0%) of 14 mucinous adenocarcinoma, and 12 (46.2%) of 26 clear-cell adenocarcinoma (P < 0.0001, clear-cell vs other histologies).
  • In conclusion, SLC22A16 was abundantly expressed in clear-cell adenocarcinoma.
  • Our results suggest that adriamycin-related chemicals that are taken up via SLC22A16 may have the potential to be effective against clear-cell adenocarcinoma.
  • [MeSH-major] Adenocarcinoma, Clear Cell / metabolism. Antibiotics, Antineoplastic / pharmacokinetics. Doxorubicin / pharmacokinetics. Organic Cation Transport Proteins / biosynthesis. Ovarian Neoplasms / metabolism


100. Botana Rial M, Fernández-Villar A, González Piñeiro A, Leiro Fernández V: [Primary lung adenocarcinoma with ovarian metastasis: a rare presentation of bronchogenic carcinoma]. Arch Bronconeumol; 2009 Nov;45(11):571-2
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary lung adenocarcinoma with ovarian metastasis: a rare presentation of bronchogenic carcinoma].
  • [Transliterated title] Adenocarcinoma de origen pulmonar con enfermedad metástasica en ovario: una forma rara de presentación de carcinoma broncogénico.
  • [MeSH-major] Adenocarcinoma / secondary. Carcinoma, Bronchogenic / secondary. Lung Neoplasms / pathology. Neoplasms, Multiple Primary / pathology. Ovarian Neoplasms / secondary

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19467750.001).
  • [ISSN] 1579-2129
  • [Journal-full-title] Archivos de bronconeumología
  • [ISO-abbreviation] Arch. Bronconeumol.
  • [Language] spa
  • [Publication-type] Case Reports; Letter; Research Support, Non-U.S. Gov't
  • [Publication-country] Spain
  •  go-up   go-down






Advertisement